<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infusion reactions to systemic chemotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infusion reactions to systemic chemotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infusion reactions to systemic chemotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mariana C Castells, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ursula A Matulonis, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terzah M Horton, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Franklin Adkinson, Jr, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Virtually all chemotherapeutic agents have the potential to initiate infusion reactions, defined in this review as unexpected reactions that cannot be explained by the known toxicity profile of the drug. The cytotoxic agents that are most commonly associated with infusion reactions are the taxanes, platinum drugs, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, asparaginase, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, and <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a>. While these are often referred to as "hypersensitivity reactions," many do not have a proven immunologic mechanism. Thus, the term infusion reaction is preferred. In contrast, allergic reactions where a known immunologic mechanism can be demonstrated through blood or skin testing are clearly established for platinum drugs, taxanes, some monoclonal antibodies, and certain other chemotherapy agents, as discussed in this review.</p><p>After an introductory section that summarizes the characteristics of infusion reactions and different approaches to classifying them, this review will focus on commonly used conventional cytotoxic drugs with a moderate to high incidence of infusion reactions, and the ways in which these reactions can be treated and/or prevented. Infusion reactions in patients receiving therapeutic monoclonal antibodies for cancer treatment are discussed separately, as are other cutaneous adverse effects associated with chemotherapy. (See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a> and  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CHARACTERISTICS OF REACTIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Signs and symptoms of infusion reactions</span><span class="headingEndMark"> — </span>Infusion reactions may affect any organ system in the body. Most are mild in severity, although severe and even fatal reactions occur. The most common signs and symptoms of infusion reactions are:</p><p class="bulletIndent1"><span class="glyph">●</span>Flushing</p><p class="bulletIndent1"><span class="glyph">●</span>Itching</p><p class="bulletIndent1"><span class="glyph">●</span>Alterations in heart rate and blood pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea or chest discomfort</p><p class="bulletIndent1"><span class="glyph">●</span>Back or abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Fever and/or shaking chills</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea, vomiting, and/or diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Various types of skin rashes</p><p class="bulletIndent1"><span class="glyph">●</span>Throat tightening</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxia </p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness and/or syncope</p><p></p><p>In this review, infusion reactions involving these symptoms will be referred to as "standard infusion reactions" or SIRs. These represent the majority of reactions to systemic chemotherapeutic agents.</p><p class="headingAnchor" id="H4"><span class="h2">Signs and symptoms of anaphylaxis</span><span class="headingEndMark"> — </span>Anaphylaxis is a distinct reaction that is rare with most conventional cytotoxic agents, although it is well established that the platinum drugs and the taxanes can cause anaphylaxis. The most common signs and symptoms of anaphylaxis caused by intravenously-administered medications are the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous symptoms</strong> – Flushing, itching, urticaria, and/or angioedema (usually of face, eyelids, or lips)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory symptoms</strong> – Repetitive cough, sudden nasal congestion, shortness of breath, chest tightness, wheeze, sensation of throat closure or choking, and/or change in voice quality (due to laryngeal edema), hypoxia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular symptoms</strong> – Faintness, tachycardia (or less often bradycardia), hypotension, hypertension and/or loss of consciousness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – Nausea, vomiting, abdominal cramping, and/or diarrhea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular symptoms</strong> – Sense of impending doom, tunnel vision, dizziness, and/or seizure, severe back, chest, pelvic pain </p><p></p><p>The clinical manifestations of anaphylaxis (from all causes) are presented in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>Although there is overlap between the clinical features of anaphylaxis and those of SIRs, certain signs and symptoms are highly suggestive of anaphylaxis, and they should be specifically sought when evaluating a patient with an infusion reaction: urticaria, repetitive cough, wheeze, throat tightness/change in voice, and hypotension. These stereotypical signs and symptoms result from the release of mediators from mast cells and basophils. In contrast, fever and prominent muscular pain are NOT features of anaphylaxis, and the presence of these signs and symptoms suggests the reaction is an SIR.</p><p>It is critical to undress the patient and examine the skin carefully during infusion reactions in order to fully appreciate skin findings, especially urticaria. The neck, trunk, extremities, abdomen, and axillae are the sites where urticaria often appears first.</p><p class="headingAnchor" id="H5"><span class="h2">Timing and risk factors</span><span class="headingEndMark"> — </span>As a group, infusion reactions (including both SIRs and anaphylaxis) usually occur during or within a few hours of drug infusion. Occasionally, a reaction may occur one to two days after administration, and patients must be adequately informed of symptoms to watch for and the appropriate course of action to take if a problem arises. Although they most commonly occur with the first or second drug administration, infusion reactions are unpredictable and can occur at any time despite preventive measures.</p><p>Attempts to identify patients who are likely to develop an infusion reaction have met with limited success, although infusion reactions are generally more common in the following settings [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>With IV as compared to oral or intraperitoneal administration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After multiple cycles of certain agents (see <a class="local">'Platinum drugs'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a prior infusion reaction to a drug of the same chemical class</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of multiple drug allergies, regardless of drug class</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLASSIFICATION OF INFUSION REACTIONS</span></p><p class="headingAnchor" id="H7"><span class="h2">National Cancer Institute classification</span><span class="headingEndMark"> — </span>The most recent version of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fctep.cancer.gov%2FprotocolDevelopment%2Felectronic_applications%2Fctc.htm&amp;token=L1PKi7ksomh1JqUfTKWNe61gdDEj7%2FEN0gFsM2jnisnZ9aDYBZ%2FnKF0Y6hAnywy9MOvaze9hPSMvHYdMdeBk6asiYcR9Y9yHOUcUYVkBUtI%3D&amp;TOPIC_ID=2835" target="_blank">National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)</a> for grading adverse reactions during chemotherapy administration has a scale for grading the severity of infusion reactions  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>) and separate grading scales for allergic reactions (which are appropriate for non-infusional medications) and anaphylaxis  (<a class="graphic graphic_table graphicRef91249" href="/d/graphic/91249.html" rel="external">table 2</a>). </p><p>Allergists/immunologists have a different approach to classifying infusion reactions, which divides them into reactions with features of mast cell or basophil activation (signifying potential progression to anaphylaxis) and those without such features (ie, standard infusion reactions [SIRs]). This approach is intended to identify patients at risk for anaphylaxis upon re-exposure, regardless of the severity of the initial reaction.</p><p>Patients with even mild symptoms of mast cell/basophil activation (eg, urticaria and dyspnea) must be treated with caution, because re-exposure to the causative agent could result in a fulminant and severe anaphylaxis. One of the authors (MC) is aware of unpublished cases in which failure to recognize anaphylaxis and manage it appropriately led to fatalities upon re-exposure to the causative drug, despite the premedications and reduced infusion rates that would have adequately managed most SIRs.</p><p>Thus, oncologists and other specialists working with chemotherapy drugs (eg, rheumatologists) should be familiar with the characteristics of anaphylactic reactions and manage these rare reactions differently from SIRs. We recommend that patients with even mild signs or symptoms of anaphylaxis not be re-exposed to the causative agent until they have been evaluated by an allergy specialist with experience in drug allergy and desensitization [<a href="#rid3">3</a>]. In particular, these patients should NOT be considered candidates for additional premedication and an attempt at drug readministration using a slower rate of infusion.</p><p class="headingAnchor" id="H8"><span class="h2">Anaphylaxis</span><span class="headingEndMark"> — </span>Anaphylaxis is defined as a serious allergic or hypersensitivity reaction that is rapid in onset and may cause death [<a href="#rid4">4,5</a>]. The diagnosis is based on clinical signs and symptoms  (<a class="graphic graphic_table graphicRef72225" href="/d/graphic/72225.html" rel="external">table 3</a>) [<a href="#rid4">4</a>]. (See <a class="local">'Signs and symptoms of anaphylaxis'</a> above and <a class="local">'Agents associated with anaphylaxis'</a> below.)</p><p>A common diagnostic mistake is equating anaphylaxis with anaphylactic shock and failing to recognize milder forms of anaphylaxis. Anaphylactic shock is the extreme end of a spectrum, but the goal should be recognition and appropriate management of anaphylaxis in its milder forms, when it is more amenable to treatment and interventions can be undertaken to prevent subsequent, more severe reactions. For example, a patient who develops limited urticaria and mild wheezing after receiving a cytotoxic agent meets diagnostic criteria for anaphylaxis  (<a class="graphic graphic_table graphicRef72225" href="/d/graphic/72225.html" rel="external">table 3</a>).</p><p>If an infusion reaction includes signs and symptoms of anaphylaxis, administration of the drug should be stopped immediately. The patient should <strong>not</strong> be considered a candidate for premedication or drug readministration at a slower rate of infusion [<a href="#rid6">6</a>]. Instead, referral to an allergist should be arranged. In the future, the patient will either need to be changed to a different and non-cross-reacting drug or receive the drug that caused the reaction through a desensitization procedure.</p><p class="headingAnchor" id="H1521976336"><span class="h3">Mechanisms</span><span class="headingEndMark"> — </span>Anaphylaxis was traditionally defined as a constellation of symptoms and signs that arose from an IgE-mediated reaction that resulted in widespread activation of mast cells and basophils throughout the body and massive release of vasoactive mediators, including histamine and tryptase. However, the definition was subsequently broadened to include any mechanism that causes widespread activation of these cells, which can sometimes involve additional cell types [<a href="#rid7">7</a>].</p><p>In classic IgE-mediated anaphylaxis, repeated exposure to a medication, such as a platinum drug, results in sensitization, or the production of drug-specific IgE antibodies, in susceptible individuals. The IgE antibodies then coat the surface of mast cells and basophils, binding to surface IgE receptors. When the drug is given again, the surface-bound IgE binds the drug, resulting in crosslinking of the surface IgE receptors, triggering an activation cascade. IgE-mediated anaphylaxis can also occur with a first exposure, presumedly due to previous IgE sensitization to cross-reactive substance. <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">Carboplatin</a> is an example of a drug that causes classic IgE-mediated anaphylaxis.</p><p>In the broader definition of anaphylaxis, mast cells and basophils can become activated through additional non-IgE-mediated mechanisms, or other immune cells, including T lymphocytes and macrophages, may be predominantly responsible, releasing cytokines in addition to vasoactive mediators [<a href="#rid7">7,8</a>]. Examples of chemotherapy agents that cause reactions through these other mechanisms include <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and taxanes.</p><p class="headingAnchor" id="H10"><span class="h3">Evaluation of anaphylaxis</span><span class="headingEndMark"> — </span>Evidence that a reaction was anaphylaxis can be obtained from blood tests collected at the time of the reaction and from skin testing, a technique employed by allergy specialists to identify drugs which are capable of causing mast cell activation, especially through IgE-mediated immune mechanisms. These two diagnostic tools are discussed in this section.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum tryptase to support the diagnosis of anaphylaxis</strong> – Mast cells and basophils contain various chemical mediators that are transiently released into the circulation during anaphylaxis. Serum total tryptase is the laboratory test that is most useful because it is nearly exclusively released by mast cells and basophils. An elevation in tryptase following a reaction provides evidence that mast cells and basophils were involved. Tryptase levels usually peak within three hours of the onset of symptoms, so blood should be drawn one to three hours after the reaction occurs. Blood drawn ≤30 minutes from the onset of symptoms may be falsely negative. Blood can be collected in a standard red top tube and serum should be frozen (at zero degrees Celsius) if it cannot be assayed promptly. Tryptase in frozen serum is stable for up to one year. Note that elevations in tryptase are not seen in all episodes of anaphylaxis, so the absence of this finding does not exclude anaphylaxis.</p><p></p><p class="bulletIndent1">The upper limit of normal for serum total tryptase is approximately 11 ng/mL, depending on the assay system. A clinically significant elevation is defined as a 20 percent increase over baseline + 2 ng. The equation for calculating a significant increase in tryptase is ≥(1.2 x baseline tryptase level + 2 ng) [<a href="#rid9">9</a>]. Elevations in anaphylaxis can range from marginally elevated to greater than 1000 ng/mL. Note that in patients with low normal baseline tryptase levels, a significant elevation can be present even if the post-event tryptase is &lt;11 ng/mL. For example, if a patient's baseline tryptase is 3 ng/mL, any increase above (1.2 x 3 ng/mL + 2 ng/mL) or 5.6 ng/mL is considered significant. The patient's baseline level can be assessed after symptoms have resolved for at least 24 hours. The interpretation of tryptase levels in anaphylaxis is discussed separately. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1">A genetic condition called hereditary alpha tryptasemia, identified in 2014 and present in up to 6 percent of the general population, is associated with more severe anaphylaxis and may be important to identify in patients with chemotherapy-induced reactions. (See  <a class="medical medical_review" href="/d/html/135236.html" rel="external">"Hereditary alpha-tryptasemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin testing to evaluate anaphylaxis</strong> – Skin testing is a technique used by allergy specialists to determine if a drug is capable of activating mast cells in the skin and therefore potentially able to cause anaphylaxis if administered systemically. The utility of skin testing is best established in the evaluation of reactions to the platinum drugs and may be useful in some patients with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> reactions (although this is not routine practice). If a patient's reaction was suggestive of anaphylaxis but tryptase levels were not elevated, skin testing may still be informative. (See <a class="local">'Skin testing'</a> below and <a class="local">'Drug versus vehicle'</a> below.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">USE OF PREMEDICATION TO PREVENT INFUSION REACTIONS</span><span class="headingEndMark"> — </span>Premedication can help prevent and/or reduce the severity of infusion reactions, particularly standard infusion reactions (SIRs). In contrast, premedication does <strong>not</strong> prevent anaphylaxis in most cases, although the severity of the reaction may be reduced.</p><p>Pharmacologic prophylaxis with antihistamines, glucocorticoids, or both is recommended for certain drugs that have a high incidence of infusion reactions (eg, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">cabazitaxel</a>, asparaginase). Antihistamines (H1 and H2 receptor antagonists) are used to proactively reduce the effects of histamine, one of the many mediators released by mast cells when they become activated, although they do not prevent mast cell activation and all its other resultant effects. Glucocorticoids suppress the activation and proinflammatory functions of many types of immune cells, although they cannot prevent mast cell activation or anaphylaxis and are not recommended as first-line treatment for anaphylaxis. There is evidence for increased side effects from steroids when used at high doses for the prevention or treatment of anaphylaxis, without demonstrated benefits. Most premedication regimens have been derived empirically rather than established through randomized trials. Because premedication is not completely protective, even for SIRs, it is important to monitor patients closely during and immediately after all chemotherapy infusions. Specific prophylactic regimens that are recommended for individual drugs are discussed below.</p><p class="headingAnchor" id="H12"><span class="h1">PRINCIPLES OF TREATMENT AND RECHALLENGE</span><span class="headingEndMark"> — </span>Clinicians should be prepared for an infusion reaction to occur during each drug administration, and standing orders should be in place to allow immediate intervention if symptoms occur, without waiting for the clinician [<a href="#rid10">10</a>]. Medical equipment and supplies needed for resuscitation (pharmacologic agents such as <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, antihistamines, intravenous fluids, and aerosolized bronchodilators as well as oxygen, tracheostomy equipment, and a defibrillator) should be readily available in any area where chemotherapy is administered.</p><p>Treatment of an infusion reaction and possible rechallenge depends upon the type and severity or the reaction.</p><p class="headingAnchor" id="H13"><span class="h2">Treatment of mild to moderate standard infusion reactions</span><span class="headingEndMark"> — </span>Mild to moderate standard infusion reactions (SIRs; ie, National Cancer Institute [NCI] grades 1 and 2 and infusion reactions that do not involve symptoms of anaphylaxis  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)) are the most commonly encountered reactions. These can usually be managed with temporary interruption of the infusion and symptom management. (See <a class="local">'Characteristics of reactions'</a> above.)</p><p class="headingAnchor" id="H14"><span class="h3">Rechallenge</span><span class="headingEndMark"> — </span>After all symptoms have resolved, rechallenge with a reduced infusion rate and additional premedication is usually successful, with the important exception of patients treated with platinum agents. <strong>We do not recommend rechallenging patients with platinum agents, even with additional premedications.</strong> Instead, we advocate referral to an allergist for skin testing. If skin testing is positive, the patient should either avoid any future exposure to the drug or receive it only through a desensitization protocol.</p><p>For patients who have recurrent SIRs despite premedication, desensitization protocols have allowed for continued use of the drug in some cases. Referral to an allergy specialist with experience in drug desensitization is an option for such patients, as a wider range of desensitization techniques can be considered [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Treatment of anaphylaxis and severe standard infusion reactions</span><span class="headingEndMark"> — </span>Reactions with <strong>any</strong> features of anaphylaxis  (<a class="graphic graphic_table graphicRef91249" href="/d/graphic/91249.html" rel="external">table 2</a>) or severe SIRs (NCI grade 3 or higher  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)) require discontinuation of the drug infusion and immediate treatment with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> and antihistamines.</p><p>Prompt recognition and treatment are critical in anaphylaxis. In series of fatal anaphylaxis from all causes, death typically ensues within 30 minutes from exposure to the trigger. Detailed guidelines for the management of anaphylaxis are available from the Joint Council of Allergy, Asthma, and Immunology, which are summarized in a rapid overview table for adults  (<a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 4</a>) and children  (<a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 5</a>) [<a href="#rid4">4</a>]. Similar recommendations have been made in the American Heart Association (AHA) Advanced Cardiac Life Support (ACLS) guidelines [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>The initial management of anaphylaxis includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Stop the infusion of the suspect medication</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Placement of the patient in the recumbent position to maintain blood flow to vital organs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intramuscular injection of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>  (<a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 5</a>) in the lateral aspect of the quadriceps muscle</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supplemental oxygen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Volume resuscitation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous antihistamines  (<a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 5</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Rechallenge after a severe standard infusion reaction</span><span class="headingEndMark"> — </span>Following a severe SIR (NCI grade 3 or higher  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)), rechallenge is usually discouraged. This is particularly true if the SIR included any symptoms suggestive of an allergic reaction, such as urticaria or angioedema [<a href="#rid6">6</a>]. In most cases, the mechanism of severe SIRs is not known, and so it is difficult to predict the best technique for preventing recurrence. If a patient is felt to be a candidate for continuation of therapy because there is potential clinical benefit of further treatment and no other reasonable alternatives exist, then we suggest desensitization, as this technique offers the most graduated and controlled manner of administration. At the author's institution (MC), these reactions are managed in the same manner as anaphylaxis, with uniformly good outcomes [<a href="#rid7">7,12</a>]. (See <a class="local">'Management after anaphylaxis'</a> below.)</p><p class="headingAnchor" id="H17"><span class="h3">Management after anaphylaxis</span><span class="headingEndMark"> — </span>Rechallenge should not be attempted for suspected anaphylaxis. The platinum drugs, which are strongly associated with IgE-mediated anaphylactic reactions, cause recurrent reactions upon rechallenge in approximately 50 percent of cases. Instead, we suggest referral to an allergy specialist with experience in drug desensitization [<a href="#rid3">3</a>]. With rare exception [<a href="#rid13">13</a>], oncologists lack the expertise to evaluate and manage these patients by themselves.</p><p>Mast cells and basophils, the cells involved in anaphylaxis, can be temporarily hyporesponsive immediately after a reaction and may be unable to be activated further. This phenomenon has probably contributed to the confusion that currently exists in the medical literature about the safety of rechallenge following severe infusion reactions. However, this phenomenon is unpredictable, and the patient is at high risk for a recurrence of anaphylaxis as soon as the cells have recovered their sensitivity, a process which takes days to weeks. Therefore, we <strong>do not</strong> recommend that patients be rechallenged after a reaction with symptoms of anaphylaxis.</p><p class="headingAnchor" id="H18"><span class="h3">Overview of skin testing</span><span class="headingEndMark"> — </span>Skin testing (using the prick/puncture and intradermal methods) is the primary diagnostic tool used by allergists to evaluate patients who have experienced an infusion reaction that included any symptoms suggestive of possible anaphylaxis. When indicated, skin testing is generally performed by allergy/immunology specialists, with specific training in the technique, proper interpretation of results, and management of the rare allergic reactions that occur in response to the testing itself.</p><p>Skin testing with chemotherapy agents is best characterized for the platinum drugs and taxanes, as discussed below. (See <a class="local">'Platinum drugs'</a> below and <a class="local">'Taxanes'</a> below.)</p><p>Skin testing with other chemotherapy drugs can also be performed, provided the drug is not a vesicant or known to cause skin necrosis upon extravasation  (<a class="graphic graphic_table graphicRef67517" href="/d/graphic/67517.html" rel="external">table 6</a>). In contrast, drugs with irritant properties can be used for skin testing, but this must be done carefully, with dilutions of the drug that have been shown to be nonirritating to the skin. (See  <a class="medical medical_review" href="/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.)</p><p>Allergists perform prick/puncture tests first, followed by intradermal tests if the prick/puncture tests are negative. This is done because prick/puncture testing is less likely to induce a systemic allergic reaction in highly sensitive patients and also less likely to produce false positive, irritant responses. If prick/puncture testing is negative, then intradermal testing is performed. Intradermal testing delivers more drug to cutaneous mast cells and is therefore more sensitive than prick/puncture testing. Appropriate positive (eg, histamine) and negative (<a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or diluent for the therapeutic agent) must always be included.</p><p>In patients who have experienced a significant infusion reaction or anaphylaxis, skin testing is usually deferred for at least one to two weeks, since false negative results are possible immediately after a severe reaction due to hyporeactivity of cutaneous mast cells [<a href="#rid14">14</a>]. However, in patients with nonanaphylactic symptoms, testing may be performed sooner if necessary, since positive tests are still meaningful. The technique of skin testing is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Positive skin test results indicate that the patient is at significant risk for anaphylaxis if the drug is given again without precautions. Desensitization should be performed before readministration of the agent if there is no equivalent substitute therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Negative skin test results indicate that the drug in question could be readministered through a graded challenge protocol, with additional premedications.</p><p></p><p class="headingAnchor" id="H19"><span class="h3">Overview of desensitization</span><span class="headingEndMark"> — </span>Desensitization involves readministration of the implicated drug in a highly controlled manner using a series of sequential steps in which the dose is gradually increased. Desensitization is indicated for infusion reactions that have features of anaphylaxis. The technique can also be applied to severe SIRs that recur despite slower rates of infusion and premedications. Important points regarding this technique include:</p><p class="bulletIndent1"><span class="glyph">●</span>Desensitization is absolutely contraindicated in patients with a history of chemotherapy-induced blistering or exfoliative dermatitis, Stevens-Johnson syndrome, or toxic epidermal necrolysis. Re-exposure in this setting can induce a fatal recurrence. (See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desensitization is not effective in preventing the recurrence of other idiosyncratic immunologic reactions such as serum sickness, hemolytic anemia, or drug fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desensitization should only be carried out under close medical supervision by experienced individuals who are comfortable with emergency management of anaphylaxis. In our view, all desensitization protocols should be performed by allergists, although as noted above, there are rare institutions at which experienced oncologists handle desensitization protocols by themselves [<a href="#rid13">13</a>].</p><p></p><p>Drug desensitization protocols are based upon stepwise administration of increasing doses of medication, such that exposure begins at very low doses, increases gradually, and is uninterrupted. The protocols presented herein have been performed successfully in published reports, although modifications may be needed in individual cases, and experience with the technique is invaluable. Symptoms during the desensitization procedure are usually mild and occur most often during the final step [<a href="#rid12">12</a>]. Clinicians should avoid altering successful protocols to render them faster or significantly change the time interval between doses. Faster protocols may be acceptable for some types of infusion reactions, but are less likely to be successful in patients with IgE-mediated anaphylaxis [<a href="#rid15">15</a>]. Therefore, the authors suggest not using abbreviated protocols to desensitize to agents (such as the platinum drugs) in which an IgE-mediated mechanism has been implicated in infusion reactions.</p><p>Desensitization induces a state of temporary tolerance to a drug that is dependent on continuous exposure. The state of tolerance is lost once the drug is cleared. Therefore, <strong>patients must be counseled that they remain allergic to the drug and must be desensitized for each subsequent administration</strong>.</p><p>At some institutions, initial desensitizations are carried out in the medical intensive care unit, although there is accumulating evidence that desensitizations for any severity of hypersensitivity reaction can be safely performed at outpatient facilities under the care of allergists and experienced nurses [<a href="#rid16">16</a>]. If the procedure is well tolerated, subsequent desensitizations can be performed on standard hospital floors or in hospital-associated infusion units with one-on-one nursing, using established policies and procedures, and after appropriate training of the nursing staff on desensitization procedures. Patients without cardiac comorbidities and with mild initial reactions can undergo their first desensitization in an outpatient facility, under the supervision of the allergist and with one-to-one nursing care.</p><p class="headingAnchor" id="H20"><span class="h1">AGENTS ASSOCIATED WITH ANAPHYLAXIS</span><span class="headingEndMark"> — </span>The platinum drugs and the taxanes are the chemotherapeutic agents that most commonly cause anaphylaxis. However, any drug can cause anaphylaxis in a susceptible individual, and reactions with features of anaphylaxis have been reported with asparaginase, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, and <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a>. (See <a class="local">'Signs and symptoms of anaphylaxis'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h1">PLATINUM DRUGS</span></p><p class="headingAnchor" id="H23"><span class="h2">Incidence and characteristics of reactions</span><span class="headingEndMark"> — </span>The platinum drugs have all been associated with anaphylaxis, particularly after repeated cycles. The overall incidence ranges from 10 to 27 percent and typically occurs after the patient has completed an initial course of treatment, experienced a disease recurrence, and resumed therapy with the same platinum agent, or following at least six to seven cycles of continuous treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate reactions</strong> – Most infusion reactions with the platinum drugs (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>) are classic type I IgE-mediated allergic reactions, which are also called immediate reactions. With the platinum drugs in particular, common symptoms of mild immediate reactions are pruritus (especially of the palms and soles), flushing, and sometimes urticaria. More severe immediate reactions can start with these same mild symptoms, but progress to include nausea, abdominal bloating and/or diarrhea, chest tightness, throat tightness, hypotension, and desaturation  (<a class="graphic graphic_table graphicRef72225" href="/d/graphic/72225.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed reactions</strong> – A few cases of type II (immune-mediated hemolytic anemia or thrombocytopenia) and type III reactions (delayed vasculitic urticaria) have been described with platinum drugs  (<a class="graphic graphic_table graphicRef71375" href="/d/graphic/71375.html" rel="external">table 7</a>) [<a href="#rid16">16-25</a>]. Skin testing and desensitization have no role in type II and III reactions, and the causative drug should be avoided in the future.</p><p></p><p class="headingAnchor" id="H1781526500"><span class="h2">Premedication</span><span class="headingEndMark"> — </span>Most centers do not routinely administer premedication before infusion of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> because of the lack of data demonstrating that any premedication regimen successfully prevents infusion reactions. However, with oxaliplatin, the available data regarding benefit from a prophylactic regimen are conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>In one series of 272 patients receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, 48 patients (18 percent) developed infusion reactions despite the use of a primary prevention regimen of <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (8 mg) prior to all treatment cycles (with the addition of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> after cycle 4) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other investigators have suggested benefit from higher doses of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in conjunction with an H1 plus an H2 receptor blocker [<a href="#rid27">27</a>]. In a retrospective cohort study of 181 patients receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus short-term infusional FU (the FOLFOX regimen) for colon cancer, one cohort received standard premedication (dexamethasone 8 mg plus <a class="drug drug_general" data-topicid="8501" href="/d/drug information/8501.html" rel="external">granisetron</a>) prior to chemotherapy while a second cohort received higher doses of dexamethasone (20 mg) plus <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> (50 mg) and <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> (20 mg) in addition to granisetron, starting with the sixth cycle of chemotherapy. The cohort receiving additional premedication had a lower incidence of hypersensitivity reactions (7 versus 20 percent), and the median number of treatment cycles increased from 9 to 12.</p><p></p><p>Although increased premedication with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> may decrease the rate of hypersensitivity reactions, patients who react to <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> need to be skin tested and evaluated for desensitization because increased premedication does not prevent anaphylaxis.</p><p class="headingAnchor" id="H24"><span class="h2">Carboplatin and cisplatin</span><span class="headingEndMark"> — </span>The overall incidence of infusion reactions (of all types) with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is approximately 12 percent [<a href="#rid1">1</a>]. The incidence is higher with repeated courses of therapy. The characteristics of infusion reactions to carboplatin are typical of anaphylaxis, with pruritus (particularly of the palms and soles), flushing, urticaria, facial swelling, wheezing, chest tightness, dyspnea, abdominal cramping, and hypotension [<a href="#rid1">1,28-30</a>]. Patients may also report "not feeling right" or a sense of impending doom. One series described a case in which isolated chest pain progressing to cardiac arrest was the only detectable symptom [<a href="#rid31">31</a>]. We have had two similar cases referred to our center, in which patients reacted to carboplatin infusions with flushing and syncope followed by cardiac arrest (unpublished data).</p><p>The incidence of infusion reactions with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is not as well reported. In early trials, incidence rates were between 5 and 14 percent [<a href="#rid32">32,33</a>]. As with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, the incidence is higher in patients who receive a greater number of courses [<a href="#rid34">34</a>] and possibly in those undergoing concomitant cisplatin-based chemoradiotherapy, for unclear reasons [<a href="#rid35">35</a>]. Some authors suggest that incidence rates have declined over time [<a href="#rid36">36</a>]. Multiple factors may have contributed:</p><p class="bulletIndent1"><span class="glyph">●</span>Current regimens commonly include pretreatment glucocorticoids as a routine component of the antiemetic regimen, particularly with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In common diseases such as lung cancer, there is an appreciation that patients require fewer cycles of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and/or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> to achieve therapeutic end points than the number they may have received in the past. Many patients receive no more than four to six cycles of treatment, which is associated with a lower rate of infusion reactions [<a href="#rid1">1</a>]. </p><p></p><p class="headingAnchor" id="H1639219081"><span class="h3">Higher-risk groups</span><span class="headingEndMark"> — </span>Patient groups at higher risk for reactions to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> include individuals with relapsed disease, those with BRCA mutations, and children with brain tumors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with relapsed disease</strong> – The incidence of infusion reactions increases with repeated drug exposure [<a href="#rid1">1</a>]. A common scenario is a reaction developing after a patient with epithelial ovarian cancer has completed a first course of therapy (often six cycles of a platinum-containing regimen), and restarted treatment with the same regimen at the time of a disease recurrence. Typically, this corresponds to the seventh to tenth exposure to the drug [<a href="#rid1">1,12,28,37,38</a>]. (See  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p></p><p class="bulletIndent1">One center described an approach that appeared to prevent/delay infusions reactions to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> in women<strong> without</strong> a history of platinum-induced infusion reactions, but who were at high risk because they required retreatment with platinum drugs for relapsed ovarian and related cancers [<a href="#rid39">39</a>]. In this retrospective series, patients received carboplatin using a graduated infusion protocol that was essentially a short desensitization (1 percent of the total dose in the first hour, 9 percent in the second hour, and 90 percent in the third hour), combined with premedications [<a href="#rid39">39</a>]. Premedications consisted of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 20 mg the night before and again the morning of infusion, with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and <a class="drug drug_general" data-topicid="9853" href="/d/drug information/9853.html" rel="external">ranitidine</a> (each 50 mg intravenously [ranitidine is no longer available in the United States]) given immediately before infusion. In an analysis of 707 patients treated over a 10-year period in the outpatient setting, the incidence, timing, and severity of infusion reactions in 174 patients given the three-hour protocol with premedication were compared with those of 533 patients who continued to receive the usual 30-minute infusion. Infusion reactions occurred in a lower percentage of patients receiving the three-hour infusion (3.4 versus 11 percent) and the time to first infusion reaction was longer (16 versus 9 treatments).</p><p></p><p class="bulletIndent1">Prospective confirmation of these results is needed to assess the true impact of these measures in an unselected high-risk patient population. Whether this approach reduces the previously noted high rates of infusion reactions in patients with inherited mutations in one of the genes associated with hereditary breast and ovarian cancer syndrome (BRCA 1 or 2) is unknown. (See <a class="local">'Carboplatin and cisplatin'</a> above.)</p><p></p><p class="bulletIndent1">However, for patients requiring re-exposure to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> for treatment of recurrent ovarian cancer, empiric use of this protocol is an alternative to continuing with a standard 30 minute platinum infusion. This approach has been adopted at a number of institutions. If the patient develops a hypersensitivity reaction with any symptoms suggestive of anaphylaxis despite this approach, rechallenge should not be attempted. Instead, the patient should be referred to an allergist with experience in drug desensitization or to an oncology center that can perform formal desensitizations. (See <a class="local">'Risks of rechallenge without desensitization'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with BRCA mutations</strong> – Clinicians should have a heightened sense of awareness for infusion reactions in women with inherited mutations in one of the genes associated with hereditary breast and ovarian cancer syndrome (BRCA 1 or 2), as they appear to have a higher risk for <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> infusion reactions, and reactions occur at a lower cumulative exposure [<a href="#rid40">40,41</a>]. This was shown in an analysis of 87 patients with ovarian cancer treated with carboplatin plus <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a> on two different clinical trials [<a href="#rid40">40</a>]. Of the total 29 patients who developed an infusion reaction while receiving carboplatin, 93 percent had a deleterious BRCA mutation. When patients were categorized according to BRCA status, 48 percent of those with a deleterious mutation had a history of an infusion reaction compared with 6 percent of those without a BRCA mutation. Mutation carriers also had an onset of carboplatin infusion reaction at significantly lower cumulative dose exposure  (<a class="graphic graphic_figure graphicRef90682" href="/d/graphic/90682.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with brain tumors</strong> – A 42 percent incidence of infusion reactions has been noted in children receiving <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> for brain tumors [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Oxaliplatin</span><span class="headingEndMark"> — </span>The incidence of infusion reactions with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> seems to be increasing over time, perhaps the result of increasing clinical use for colorectal cancer [<a href="#rid26">26,42,43</a>]. Oxaliplatin infusion reactions may occur within minutes of drug administration and with any cycle of therapy. However, as with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, the incidence increases with multiple courses of therapy [<a href="#rid19">19,24,44</a>]. Most of the severe reactions represent anaphylaxis. Milder reactions can present as pruritus, fever, chills, and urticaria [<a href="#rid25">25</a>].</p><p>In several large series, acute infusion reactions were reported in 12 to 25 percent of patients treated with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>; up to one-third were severe (ie, grade 3 or worse  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)) [<a href="#rid24">24,26,42,45-47</a>]. In the largest report, 308 of 1224 (25 percent) patients developed symptoms compatible with an oxaliplatin reaction, as verified by the development of similar symptoms on rechallenge [<a href="#rid24">24</a>]. Observations based on this series included:</p><p class="bulletIndent1"><span class="glyph">●</span>Most reactions occurred after the first five treatment courses (median nine, range 1 to 24).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of patients (63 percent) had mild reactions, characterized by pruritus and small area of erythema developing during the infusion or within several hours of receiving treatment. All patients with mild reactions were able to tolerate continued treatment with additional premedication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe reactions occurred in 37 percent and were characterized by diffuse erythroderma, facial swelling, chest tightness, bronchospasm, and decrease in blood pressure, which developed within minutes of drug infusion. Although rechallenge with a lower rate of drug infusion and two to three days of premedication was attempted in these patients, fewer than one-half tolerated an additional two to four courses of therapy; the remaining patients required treatment discontinuation because of recurrence of severe reactions. Desensitization was not attempted.</p><p></p><p>Other apparently immune-mediated reactions have also been reported with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, including acute immune thrombocytopenia, immune hemolytic anemia, Evans syndrome, and possible drug-induced thrombotic microangiopathy [<a href="#rid24">24,25,48,49</a>] (see  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>). Collectively, fewer than 65 such reactions have been reported. Patients may develop fever, chills, lower back pain, hematuria, and/or bleeding, most commonly during or within 24 hours of the last infusion. Reported laboratory abnormalities include thrombocytopenia, anemia, increased bilirubin and creatinine, low haptoglobin, and proteinuria. Direct Coombs tests and antiplatelet antibodies are variably positive [<a href="#rid49">49</a>]. Following immediate oxaliplatin discontinuation, fluids, and glucocorticoids, some patients recovered over days to weeks, while others required transfusions of platelets or red blood cells, or hemodialysis, and followed a more protracted course. A small number of fatalities have been described [<a href="#rid20">20,50-52</a>]. It is not clear if there are common pathogenic mechanisms underlying these reactions, but an awareness of this spectrum of disorders related to oxaliplatin is important. Patients with these types of reactions should not receive oxaliplatin again.</p><p>It is also important to keep in mind that reactions during <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> therapy may be caused by concomitantly administered drugs. Many protocols administer oxaliplatin concurrent with <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (eg, oxaliplatin plus leucovorin and short-term infusional fluorouracil [FU], the FOLFOX regimen). In these regimens, leucovorin and oxaliplatin are usually administered simultaneously. In some cases, a presumed oxaliplatin infusion reaction in fact represents a hypersensitivity reaction to leucovorin. Referral to a drug allergy expert for skin testing and possible drug provocation testing is advised for patients treated with concurrent oxaliplatin and leucovorin if the results would alter the treatment plan. This might be the case if continuation of oxaliplatin with a different chemotherapy partner such as <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> would be considered if leucovorin was deemed responsible for the infusion reaction, or if a second-line chemotherapy regimen is being considered that also contains leucovorin (eg, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus leucovorin and short term infusional FU, FOLFIRI). (See <a class="local">'Leucovorin'</a> below and  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Capecitabine doublets'</a> and  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'The cytotoxic chemotherapy backbone'</a>.)</p><p>There is some evidence that exposure to <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> caused patients to become sensitized to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and/or <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and cross-reactivity has been demonstrated among the three platinum agents (although cisplatin has been safely administered to patients with carboplatin hypersensitivity) [<a href="#rid53">53</a>]. It is not recommended to switch platinum agents after a reaction to one without assessing skin test reactivity [<a href="#rid54">54</a>]. (See <a class="local">'Cross-reactivity among platinum drugs'</a> below.)</p><p class="headingAnchor" id="H26"><span class="h2">Risks of rechallenge without desensitization</span><span class="headingEndMark"> — </span>In most (but not all [<a href="#rid30">30</a>]) reports, at least 50 percent of patients who develop an infusion reaction to a platinum agent will react again if rechallenged, even after additional premedication [<a href="#rid37">37,42-44</a>], and fatalities have been reported [<a href="#rid55">55,56</a>]. In our view, patients with any symptoms suggestive of anaphylaxis should not be rechallenged, but instead, be referred to an allergist with experience in drug desensitization or to an oncology center with similar experience (see below).</p><p>Rechallenge should be restricted to patients with mild to moderate reactions that do <strong>not</strong> include features of anaphylaxis. However, even mild reactions can escalate to severe reactions, underscoring the need for close monitoring during rechallenge. Rechallenge can be preceded by premedication with glucocorticoids plus an H1- (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, 50 mg) and H2-histamine receptor blocker (eg, <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 20 mg) 30 minutes prior to infusion. In addition, a slower infusion rate (over three to six as compared to two hours) should be used [<a href="#rid26">26,45</a>].</p><p class="headingAnchor" id="H27"><span class="h2">Evaluation and management of patients with possible anaphylaxis</span><span class="headingEndMark"> — </span>Patients receiving platinum drugs who have infusion reactions with any features of anaphylaxis should not receive further drugs until they have been evaluated by an allergy specialist with experience in drug allergy, skin testing, and desensitization [<a href="#rid3">3</a>]. If referral to an experienced allergist is not possible, then the oncologist may either refer the patient to an oncology center with experience in skin testing and desensitization or change the patient's therapy to an alternative agent, if a reasonable alternative exists.</p><p>Tryptase is elevated in all the cases of anaphylaxis to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and it is a very useful marker if desensitization is being considered. If serum tryptase was collected at the time of the reaction and is elevated above the patient's baseline, then it can be assumed that the patient had had anaphylaxis. Elevated tryptase indicates mast cell activation with or without IgE, and such patients may not need skin testing and should only receive the platinum agent again using a desensitization protocol. (See <a class="local">'Evaluation of anaphylaxis'</a> above.)</p><p class="headingAnchor" id="H28"><span class="h3">Skin testing</span><span class="headingEndMark"> — </span>In patients who have had an infusion reaction (of any severity), skin testing reliably predicts the majority of anaphylactic reactions to platinum-type drugs, and patients who have a positive skin test should <strong>not</strong> be rechallenged without use of a desensitization protocol because the next reaction could be more severe.</p><p>Skin testing protocols have been developed to identify patients who are at risk for platinum-induced anaphylaxis and are most useful in centers at which allergists and oncologists collaborate closely [<a href="#rid29">29,57-62</a>]. Skin testing is generally performed by allergy/immunology specialists, with specific training in the technique, proper interpretation of results, and management of the rare allergic reactions that occur in response to the testing itself. (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a>.)</p><p class="headingAnchor" id="H374705551"><span class="h4">Techniques and timing</span><span class="headingEndMark"> — </span>Prick/puncture testing is performed first. If this is positive, then reactivity is confirmed and no further skin testing is required. If prick/puncture testing is negative, then intradermal testing is performed with 0.02 mL of the same drug concentration used for prick/puncture initially. If this is negative, it is followed by 0.02 mL of a 10-fold stronger concentration. Concentrations for each platinum drug are specified below:</p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, prick/puncture testing is performed with 10 mg/mL, which is equivalent to the concentration at which the drug is infused. If the patient's history suggests extreme sensitivity, prick/puncture testing is performed with lower concentrations first (eg, 1 mg/mL or lower) [<a href="#rid29">29,63</a>]. If prick/puncture is negative, intradermal testing is then performed with 1 mg/mL. If this is negative, intradermal testing is performed with 10 mg/mL, although some protocols use maximal concentrations of 3 or 5 mg/mL, and the optimal concentration has not been determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> skin testing, maximal concentrations of 1 mg/mL are used for both prick/puncture testing and intradermal testing [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> skin testing, maximal concentrations of 3 to 5 mg/mL are used for both prick/puncture testing and intradermal testing [<a href="#rid12">12,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The timing of skin testing is important because two different errors are possible [<a href="#rid65">65,66</a>]. After a severe reaction, which involves massive mast cell degranulation, the patient's mast cells may be temporarily desensitized or significantly less reactive while intracellular granules are refilling with mediators, resulting in false negative skin test results. Thus, it is best to wait at least four weeks after a severe reaction to perform skin testing. However, if the testing is performed sooner and is positive, the results should be reliable. It is also important not allow too much time to elapse after a reaction before performing skin testing, because drug-specific IgE can drop to low levels over time, also yielding false negative skin tests [<a href="#rid67">67</a>]. Therefore, we try to perform skin testing no longer than six months from the time of the reaction. For patients with very severe reactions and skin testing that was negative but was performed more than six months after the reaction, we worry that the result could be falsely negative, and we give the next dose using a graded challenge protocol, for added safety, as described in the next section.</p><p></p><p class="headingAnchor" id="H374705814"><span class="h4">Interpretation</span><span class="headingEndMark"> — </span>In patients with past immediate infusion reactions to platinum drugs, the results of skin testing, combined with the severity of the past reaction, are used to determine future management [<a href="#rid59">59,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A positive supports the diagnosis of platinum-induced anaphylaxis. Nearly all patients with past reactions that were consistent with moderate to severe IgE-mediated immediate allergy will have a positive skin test. Although not every patient with a positive skin test will react if given the drug again [<a href="#rid68">68</a>], we believe that all patients with positive skin testing should only receive the drug by desensitization in the future because platinum hypersensitivity reactions can be severe and even fatal [<a href="#rid55">55,56</a>]. (See <a class="local">'Desensitization protocols'</a> below.)</p><p></p><p class="bulletIndent1">Once a patient has developed an immediate allergy to a platinum drug, the allergy generally persists. If the patient is not exposed to the drug for several years but then requires it again for relapsed disease, we perform skin testing again before administration if there is time. The skin test may have converted to negative, and if this is the case, the patient can receive the drug normally for the first one or two cycles. However, the patient must be watched carefully for recurrent allergy (even mild symptoms), because it is likely to reappear after two or three cycles of treatment, at which point skin testing should be performed again to guide further treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The negative predictive value of skin testing was estimated at 92 percent for platinum drugs in general in one large study [<a href="#rid14">14</a>]. It was 100, 89, and 87 percent for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, respectively. However, if more than six months has elapsed between the reaction and skin testing, the negative predictive value is lower [<a href="#rid67">67</a>]. (See <a class="local">'Techniques and timing'</a> above.)</p><p></p><p class="bulletIndent1">If the patient's past infusion reaction was moderate to severe and suggestive of anaphylaxis, but skin testing to the platinum drug involved was negative, the details of the case should be re-examined carefully to determine if another agent may have been given in close proximity to the platinum (eg, <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>). If so, an infusion reaction to the other drug should be considered. (See <a class="local">'Leucovorin'</a> below.)</p><p></p><p class="bulletIndent1">If no other agent can be implicated, we recommend empiric desensitization to the platinum drug.</p><p></p><p class="bulletIndent1">If no other agent can be implicated and the past reaction was mild, then patients with negative skin tests can receive the platinum drug again using a graded challenge (also called a drug provocation test). (See <a class="local">'Graded challenge (drug provocation testing)'</a> below.)</p><p></p><p class="headingAnchor" id="H606228115"><span class="h4">Utility of skin testing in patients without reactions</span><span class="headingEndMark"> — </span>At a few centers, skin testing has been performed in patients who have received multiple courses of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> therapy but have not actually had an infusion reaction, in an effort to identify patients who may react in the future [<a href="#rid58">58,59</a>]. This is not our approach. Although a positive skin test result with platinum drugs may identify patients at higher risk to develop a later infusion reaction, not all patients with positive skin tests will develop reactions, and we have been able to manage patients safely by intervening only after symptoms have appeared. Patients who have been exposed to other platinum agents and need to be treated with a different one need skin testing before exposure due to potential cross-reactivity, as described above.</p><p>The largest study of this approach included 126 patients who were skin tested with an intradermal injection of 0.02 mL of an undiluted aliquot of the <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> preparation for infusion, performed 30 minutes prior to each planned dose [<a href="#rid59">59</a>]. All patients had gynecologic malignancies and had received at least six cycles of platinum-based chemotherapy. A positive skin test was defined as a wheal ≥5 mm in diameter with a surrounding flare (although allergy specialists typically define a positive test as a wheal ≥3 mm larger than the negative control).</p><p>Thirty-nine patients (31 percent) had a positive skin test. Six of seven patients (86 percent) with a positive skin reaction who elected to proceed with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> infusion developed an infusion reaction, compared with only 7 of 87 (8 percent) who had a negative skin test. Of the 39 patients with positive skin tests, seven others elected to undergo rechallenge using a desensitization protocol, of which six were successful. Thus, a negative test was associated with the absence of a reaction with subsequent administration, while a positive test result indicated increased risk for an infusion reaction with subsequent doses [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H606228083"><span class="h3">Graded challenge (drug provocation testing)</span><span class="headingEndMark"> — </span>At the authors' institutions, graded challenges are performed by giving patients 1/10 of a full dose (at normal concentrations and at the normal infusion rate), without premedications, followed by 30 minutes of observation. If no symptoms develop, the remaining 9/10 of the dose is given normally. If this is tolerated, it proves that the patient is not allergic at that point in time, and can continue to receive the drug normally in the future, although providers should remain vigilant for signs of reactions in these patients, particularly after multiple exposures. Other centers have published results of a similar but simplified approach, in which the challenge was not graded [<a href="#rid68">68</a>], although we believe a graded approach is safer because fatalities have been reported with re-exposure to these drugs [<a href="#rid55">55,56</a>]. (See <a class="local">'Rechallenge'</a> above.)</p><p class="headingAnchor" id="H7622392"><span class="h3">If skin testing is not available</span><span class="headingEndMark"> — </span>If a patient has experienced an infusion reaction to a platinum drug and evaluation by an allergy specialist is not possible, then the patient should be assumed to be at risk for anaphylaxis. The patient should either be treated with an alternative chemotherapy agent or only receive subsequent doses of the platinum drug in question using a formal desensitization protocol. If evaluation by an allergy specialist is not possible, and there is no reasonable alternative drug, then patients with infusion reactions that have any features of anaphylaxis (regardless of severity), patients with severe (ie, grade 3 or worse  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)) standard infusion reactions (SIRs), and patients with mild/moderate SIRs that recurred despite premedication and slower rate should be assumed to be at risk for anaphylaxis and only receive subsequent doses of the platinum drug in question using a formal desensitization protocol.</p><p class="headingAnchor" id="H29"><span class="h3">Desensitization protocols</span><span class="headingEndMark"> — </span>Clinical indications and general principles of desensitization are discussed above. As mentioned previously, desensitization induces a temporary state of tolerance and must be repeated each time the patient requires the same drug in the future. (See <a class="local">'Overview of desensitization'</a> above.)</p><p>Patients with positive skin testing after an infusion reaction to a platinum drug should only receive that platinum drug again using a desensitization protocol. Desensitization protocols for platinum drugs have been developed independently by allergists  (<a class="graphic graphic_table graphicRef51577" href="/d/graphic/51577.html" rel="external">table 8</a>) [<a href="#rid12">12,29,63</a>] and by oncologists  (<a class="graphic graphic_table graphicRef77173 graphicRef61477" href="/d/graphic/77173.html" rel="external">table 9A-B</a>) [<a href="#rid1">1,34,69-71</a>]. The authors do not suggest using abbreviated protocols for platinum drugs [<a href="#rid15">15</a>], and longer protocols (or more dilute starting solutions) may occasionally be needed [<a href="#rid72">72</a>]. Although there is less experience, desensitization protocols modeled upon those used for <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> have been used successfully to permit continued <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> treatment [<a href="#rid23">23,46,57,73,74</a>].</p><p class="headingAnchor" id="H30"><span class="h2">Cross-reactivity among platinum drugs</span><span class="headingEndMark"> — </span>Cross-reactivity based on clinical reactivity and/or skin testing between <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> has been estimated to be between 37 and 45 percent, while the cross-reactivity between <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and the other two agents appears to be much lower [<a href="#rid14">14,75</a>]. Based on these findings, patients who have reacted to either carboplatin or oxaliplatin have the lowest risk of a repeat reaction if switched to cisplatin, provided the patient has never received cisplatin in the past [<a href="#rid75">75</a>]. However, one of the authors (MC) has encountered exceptions to this observation and performs skin testing to the platinum agent that is desired for the patient's future treatment in this situation, followed by desensitization if the skin test result is positive [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/16755.html" rel="external">"Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease", section on 'Retreatment with carboplatin and risk of hypersensitivity reactions'</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">TAXANES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> are among the most widely used cytotoxic drugs. Premedication is routinely recommended to prevent infusion reactions. (See <a class="local">'Premedication regimens'</a> below.)</p><p class="headingAnchor" id="H2125498025"><span class="h2">Paclitaxel and docetaxel</span></p><p class="headingAnchor" id="H33"><span class="h3">Characteristics of infusion reactions</span><span class="headingEndMark"> — </span>Clinically, acute reactions to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> are characterized by dyspnea (with or without bronchospasm), urticaria, hypotension (or sometimes hypertension), and an erythematous rash (which may not begin until after the patient has returned home following drug infusion) [<a href="#rid6">6</a>]. Severe back, pelvic, chest, and crushing abdominal pain may also occur.</p><p>The clinical characteristics of docetaxel-related infusions reactions in a series of 102 cases included the following [<a href="#rid77">77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Facial flushing (80 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Chest discomfort/pain (67 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Back pain (51 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia (45 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Erythematous rash (36 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension (25 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus/urticaria (20 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Facial swelling (18 percent)</p><p></p><p>With both drugs, symptoms usually develop within the first 10 to 15 minutes of drug infusion, and nearly 90 percent occur during the first or second drug infusion [<a href="#rid30">30,34,78</a>]. The timing of these reactions suggests that they are mediated by a direct release of mast cell mediators such as histamine and tryptase. These reactions can occur with later infusions, even if they have not occurred with previous doses [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H3422355780"><span class="h4">Delayed reactions</span><span class="headingEndMark"> — </span>An estimated 10 to 15 percent of hypersensitivity reactions to taxanes present as delayed cutaneous reactions, beginning a few days to 10 days after taxane infusion [<a href="#rid14">14,79</a>]. The use of premedications may impact when symptoms appear, with more extensive premedication resulting in a greater delay until symptoms appear. Delayed taxane reactions can range from mildly pruritic maculopapular eruptions to urticaria and angioedema to (less commonly) dyspnea. Most resolve in several days with symptomatic treatment.</p><p>It is important to ask about delayed reactions because they can be the prelude to subsequent acute infusion reactions, including anaphylaxis [<a href="#rid6">6</a>]. For this reason, significant delayed reactions, not only those involving urticaria and angioedema, but also maculopapular rashes, should be evaluated by allergists before the drug is readministered. Both types of delayed reactions have been observed in patients that subsequently develop severe infusion reactions.</p><p class="headingAnchor" id="H643537181"><span class="h3">Incidence with paclitaxel</span><span class="headingEndMark"> — </span>In early trials, acute infusion reactions developed in up to 30 percent of patients receiving <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and were dose-limiting. After the introduction of methods to diminish the incidence and severity of infusion reactions (eg, prolonging the drug infusion, and premedication with antihistamines and glucocorticoids), the rate of severe reactions was reduced to 2 to 4 percent [<a href="#rid78">78,80-82</a>].</p><p>With appropriate premedication, the incidence of infusion reactions is approximately the same (1 to 3 percent) whether <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> is administered over 24, three, or one hour [<a href="#rid83">83,84</a>]. However, the incidence may be higher with infusion times under one hour [<a href="#rid85">85</a>]. Even with appropriate premedication, mild reactions (skin rash, flushing) still occur in a substantial number of patients. (See <a class="local">'Premedication regimens'</a> below.)</p><p class="headingAnchor" id="H643537195"><span class="h3">Incidence with docetaxel</span><span class="headingEndMark"> — </span>Based on differences in formulation, it was thought that the rate of infusion reactions with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> would be less than with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (see <a class="local">'Mechanisms of infusion reactions'</a> below). However, 30 percent of patients receiving docetaxel without premedication developed reactions [<a href="#rid86">86</a>]. Furthermore, even with standard premedication, potentially life-threatening infusion reactions occur in approximately 2 percent of docetaxel-treated patients [<a href="#rid77">77,87,88</a>]. Docetaxel-related fluid retention, which is not a true infusion reaction, is also discussed below (see <a class="local">'Other idiosyncratic reactions'</a> below).</p><p class="headingAnchor" id="H34"><span class="h3">Mechanisms of infusion reactions</span><span class="headingEndMark"> — </span>The taxanes can cause both standard infusion reactions (SIRs) and anaphylaxis. To further complicate matters, there is evidence that both the taxane component and the vehicles used to solubilize these agents are capable of causing various types of infusion reactions. (See <a class="local">'Drug versus vehicle'</a> below.)</p><p>Among the proposed mechanisms underlying <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> infusion reactions are complement activation, direct mast cell/basophil activation, and classic IgE-mediated anaphylaxis [<a href="#rid89">89</a>]. The mechanism underlying acute <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> infusion reactions is less well characterized [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H18018679"><span class="h4">Drug versus vehicle</span><span class="headingEndMark"> — </span>It is uncertain whether the taxanes themselves or the vehicles in which they are dissolved are responsible for the majority of infusion reactions [<a href="#rid91">91,92</a>].</p><p><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> is formulated in Cremophor, a vehicle that is common to other drugs that cause infusion reactions, such as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, and <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> [<a href="#rid92">92</a>]. Paclitaxel should probably be avoided in patients who have had a severe reaction to one of these drugs (although <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> may be used) (see <a class="local">'Nabpaclitaxel'</a> below). There is also some evidence that incomplete mixing of paclitaxel and Cremophor before administration may be at least partly responsible for first exposure reactivity [<a href="#rid93">93</a>].</p><p>There are multiple potential mechanisms for reactions to the taxane drugs, and this issue remains unresolved. Reactions to <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> have been attributed to the vehicle, polysorbate 80, the same vehicle used for <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> [<a href="#rid94">94</a>] (see <a class="local">'Etoposide'</a> below). In animal models, polysorbate has been shown to induce histamine release and cause hypersensitivity reactions [<a href="#rid95">95</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D9fb533da-a7ba-4c2b-8e4f-8e336ba55d12&amp;token=QyeaBAZXzH36ZZK2QXrMxfG1NEMYqucu8SRtc5Ytt3giy6GFQPhAwN9RjtDgdOQen%2BL7XgRTJNvroEAypu9ZuLdkbUpdMpzNQZRZJcze84kYC7BIUaauea8fEctZJJIe&amp;TOPIC_ID=2835" target="_blank">United States Prescribing Information for docetaxel</a> lists reactions to other drugs containing polysorbate 80 as a contraindication to administration. However, the drugs themselves may be capable of initiating infusion reactions, independent of the solvent [<a href="#rid96">96,97</a>].</p><p>Skin testing has been used for risk stratification, and patients with positive skin testing are candidates for desensitization. There is evidence that paclitaxel-sensitized patients can react to <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, indicating a common sensitizing mechanism, and that patients reactive to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> need to be skin tested for both paclitaxel and docetaxel to be able to use docetaxel [<a href="#rid79">79</a>]. In addition, patients with positive skin testing to paclitaxel may react to non-Cremophor-containing paclitaxel preparations (eg, <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>). (See <a class="local">'Nabpaclitaxel'</a> below.)</p><p class="headingAnchor" id="H35"><span class="h4">Other idiosyncratic reactions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonitis</strong> – In addition to the infusion reactions described above, there are multiple reports of acute, bilateral, transient pulmonary infiltrates developing during, within a few hours, or up to two weeks after <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> administration. In one case in which the patient was subjected to intense investigation, paclitaxel (and not Cremophor) was judged responsible, and the mechanism appeared to be a cell-mediated (type IV) delayed reactions  (<a class="graphic graphic_table graphicRef71375" href="/d/graphic/71375.html" rel="external">table 7</a>) [<a href="#rid98">98</a>]. A similar reaction has been reported rarely with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>. (See  <a class="medical medical_review" href="/d/html/4355.html" rel="external">"Taxane-induced pulmonary toxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Docetaxel</strong><strong> and fluid retention</strong> – Unlike <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> has been associated with a fluid retention syndrome that is attributed to capillary leakage [<a href="#rid82">82,99,100</a>]. Fluid retention is cumulative.</p><p></p><p class="bulletIndent1">Glucocorticoid premedication (<a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg twice daily for 24 hours before and 48 hours following each <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> dose) reduces the incidence of severe cases of fluid retention from 20 to 6 percent, reduces the number of patients discontinuing treatment because of this adverse effect from 32 to 3 percent, and increases the median cumulative dose to onset of moderate to severe fluid retention from 490 mg/m<sup>2</sup> to 790 mg/m<sup>2</sup> [<a href="#rid36">36,100,101</a>]. Lower doses are needed for weekly treatment (see <a class="local">'Premedication regimens'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Docetaxel</strong><strong> cutaneous toxicity</strong> – <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a> also causes skin toxicity that appears similar to acral erythema [<a href="#rid102">102</a>]. A unique variant, termed fixed erythrodysesthesia plaque, develops as a fixed, solitary plaque proximal to the infusion site that does not involve the palms or soles. It usually resolves with desquamation, leaving hyperpigmentation five to six weeks later.</p><p></p><p class="bulletIndent1">These effects are more likely manifestations of direct skin toxicity than infusion reactions. (See  <a class="medical medical_review" href="/d/html/142102.html" rel="external">"Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H36"><span class="h3">Premedication regimens</span><span class="headingEndMark"> — </span>Premedication with a glucocorticoid, as well as an H1 and H2 receptor antagonist, is recommended prior to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>. Premedication with a glucocorticoid alone is recommended prior to <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>.</p><p>Premedication with a glucocorticoid reduces but does not eliminate the risk of infusion reactions in patients receiving <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>. At least one fatality despite premedication has been reported [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H37"><span class="h4">Paclitaxel</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Every three week regimens</strong> – For <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> being administered every three weeks, conventional practice is to administer 20 mg of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> orally 12 and 6 hours prior to drug administration, with H1 and H2 receptor antagonists administered IV 30 minutes prior to drug infusion [<a href="#rid104">104</a>]. Using this approach, the rate of severe infusion reactions is only 1 to 2 percent, compared to 2 to 5 percent without treatment [<a href="#rid105">105</a>]. The nonsedating agent <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> may be substituted for <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> after the first two courses of treatment in the absence of an infusion reaction. At least some data suggest that prophylactic use of pemirolast, an oral mast cell stabilizing agent, may further decrease the incidence of paclitaxel-induced infusion reactions [<a href="#rid106">106</a>]. However, additional data are required to assess the role of this approach, and oral pemirolast is not available in the United States.</p><p></p><p class="bulletIndent1">While this empirically derived three drug regimen has been a standard premedication for <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> since its early development [<a href="#rid80">80</a>], there are no published trials that support benefit for an H2-receptor antagonist to prevent infusion reactions to paclitaxel. Benefit was called into question by a prospective but nonrandomized pre-post interventional noninferiority study of 366 Dutch patients undergoing a first cycle of outpatient paclitaxel for treatment of cancer; 183 initiating therapy between October 2018 and April 2019 were premedicated with a standard regimen containing <a class="drug drug_general" data-topicid="9853" href="/d/drug information/9853.html" rel="external">ranitidine</a> (a drug which has been withdrawn from the US market), while a subsequent cohort treated between April and December 2019 were treated without ranitidine [<a href="#rid107">107</a>]. The rate of infusion reactions of any grade was actually less in the group treated without ranitidine (20 versus 12 percent) as was the rate of severe infusion reactions ≥grade 3 (4.4 versus 1.6 percent). Whether these data apply to other regimens (eg, those containing <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a>) is unclear. In our view, the data are insufficient to be practice-changing.</p><p></p><p class="bulletIndent1">Alternative glucocorticoid regimens have been proposed to reduce glucocorticoid exposure. The two-dose oral glucocorticoid regimen is preferred for most patients receiving the drug on an every three week basis unless there are extenuating circumstances. However, a single 20 mg dose of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> plus antihistamines can be administered intravenously 30 minutes prior to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid91">91,108-110</a>]. This shorter prophylactic regimen has been widely adopted. A single randomized trial demonstrated no difference in either the rate of infusion reactions or severe infusion reactions with a single-dose IV versus two-dose oral dexamethasone regimen [<a href="#rid111">111</a>], and another large retrospective analysis failed to find any correlation between dexamethasone dose and incidence of hypersensitivity reactions to either paclitaxel or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid112">112</a>]. However, at least one direct comparison study showed a 10 percent higher rate of infusion reactions with one-dose IV compared with the two-dose oral regimen (17.3 versus 7.5 percent, respectively), although the majority were not severe [<a href="#rid83">83</a>]. Furthermore, a meta-analysis of six studies (including the single randomized trial [<a href="#rid111">111</a>]; the remainder were retrospective comparisons) concluded that the two-dose oral glucocorticoid regimen was associated with fewer severe infusion reactions as compared with a single IV dose [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weekly regimens</strong> – Patients who receive <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> on a weekly administration schedule have the potential to receive substantial doses of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>; ongoing glucocorticoid treatment is unnecessary for most [<a href="#rid36">36,114,115</a>]. One approach is to administer a lower dexamethasone dose (10 mg IV) with an H1 and H2 receptor blocker 30 minutes prior to the first administration of weekly paclitaxel. Glucocorticoid doses can then be safely tapered by weekly 2 mg decrements after the third or fourth week in patients without infusion reactions and then discontinued [<a href="#rid116">116,117</a>].</p><p></p><p class="headingAnchor" id="H38"><span class="h4">Docetaxel</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Every three week administration</strong> <strong>–</strong> For patients receiving <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> every three weeks, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (8 mg orally twice a day for three consecutive days) is begun 24 hours before the docetaxel infusion. This regimen is effective for reducing both the incidence/severity of infusion reactions and fluid retention [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weekly </strong><strong>docetaxel</strong> – The optimal schedule of glucocorticoid administration in patients receiving weekly <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> is unclear, and practice is variable [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1">At least two studies reported a low incidence of infusion reactions (3 percent in both studies) with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg the night before, just prior to, and the evening after the weekly dose (24 mg per week) [<a href="#rid36">36,119</a>]. Alternatively, a phase II trial of weekly <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> in 54 patients with metastatic breast cancer reported no infusion reactions with a single dose of 8 mg of dexamethasone prior to each weekly dose of docetaxel [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1">However, in at least one other trial, there was a higher incidence of infusion reactions with the first dose of weekly <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> when patients were premedicated with a single dose of 10 mg of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> immediately prior to the infusion [<a href="#rid121">121</a>]. The authors recommended dexamethasone 8 mg orally twice a day for 24 hours before the docetaxel infusion prior to the first two weekly doses, with a switch to the single dose regimen thereafter if there was no reaction after the first two weekly doses. We agree with this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with hormone refractory prostate cancer receiving </strong><strong>prednisone</strong> – For men receiving <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for hormone refractory prostate cancer, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Da630937b-8369-74ad-b68a-f940eb16ff0f&amp;token=QiIqT6hHAOaX6IifjLsFcO3kmlR9jWGV4lhzWmA47o6Q5Ta994NFp8AtEUhoJnPR%2FyD5QaWV0XDG%2FL61B75xmJP9xzVTx9qGvR6NkUAuxFuhiV7lLCiLKk%2FxeOcA0sID&amp;TOPIC_ID=2835" target="_blank">United States Prescribing information</a> recommends <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg orally at 12, 3, and 1 hour before each docetaxel dose.</p><p></p><p class="headingAnchor" id="H39"><span class="h2">Test dosing (not recommended)</span><span class="headingEndMark"> — </span>Test dosing does not predict which patients will develop initial or recurrent infusion reactions to taxanes and most oncologists do not perform it. "Screening" for hypersensitivity to taxanes by means of a test dose (prior to the first dose) was studied in a series of 206 patients receiving an initial dose of either <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> or <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, 90 of whom received a test dose (1 mg of either paclitaxel or docetaxel administered in 3 mL of normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> over two to five minutes by IV push, at least 30 minutes after premedications) [<a href="#rid122">122</a>]. Of the 22 patients who had an infusion reaction, only one of the five who required hospitalization was from the test dose group. Compared to patients who did not receive a test dose, the severity of the reaction after a test dose was significantly less (1.5 versus 3.3 on a scale of 1 to 4), and there was less need for acute hospitalization. However, others suggest that test doses are unreliable and argue against their routine use [<a href="#rid89">89</a>]. Test dosing is not a widely accepted practice.</p><p class="headingAnchor" id="H40"><span class="h2">Retreatment after an infusion reaction</span></p><p class="headingAnchor" id="H77641552"><span class="h3">Rechallenge</span><span class="headingEndMark"> — </span>Patients experiencing major infusion reactions have been successfully rechallenged after premedication with high dose glucocorticoids plus H1 and H2 receptor antagonists and taxane administration at a slower infusion rate, with or without desensitization [<a href="#rid30">30,34,68,89,123,124</a>]. In a series of 107 infusion reactions to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, 80 patients were successfully rechallenged without undergoing desensitization [<a href="#rid30">30</a>]. Clinical indications and general principles of desensitization are discussed above. (See <a class="local">'Overview of desensitization'</a> above.)</p><p>One study readministered <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> to seven patients with past severe reactions and one with a mild reaction, using a protocol of escalating infusion rates, combined with premedication [<a href="#rid34">34</a>]. The calculated total dose was mixed in 1000 cc, and the infusion was initiated at 3 to 6 cc/hour, and increased by 6 cc/hour every 10 to 15 minutes until reaching a maximum rate of 42 cc/hour. For patients who had only a mild reaction, treatment was initiated at 21 cc/hour for one hour, then if tolerated, the infusion was increased to 42 cc/hour. Seven of the eight patients were successfully treated using this approach.</p><p class="headingAnchor" id="H27068615"><span class="h3">Skin testing</span><span class="headingEndMark"> — </span>Skin testing is positive in over 30 percent of patients with severe taxane hypersensitivity reactions and is recommended to assess the risk of further reactions in future treatments [<a href="#rid79">79,96</a>]. The negative predictive value of skin testing with taxane drugs was 100 percent in one large study [<a href="#rid14">14</a>].</p><p>The concentrations used for <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> skin testing at the author's clinic are 1 mg/mL for prick/puncture testing. If prick puncture testing is negative, it should be followed by 0.001 mg/mL and then 0.01 mg/mL paclitaxel administered intradermally [<a href="#rid79">79</a>]. For <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, the concentration for prick/puncture testing is 0.4 mg/mL in normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. If negative, it is 0.04 mg/mL and then 0.4 mg/mL docetaxel administered intradermally. If skin test results to any step are positive, the patients should receive any further doses of paclitaxel or docetaxel using a desensitization protocol. If negative, the patient can be rechallenged with premedications and a slower infusion rate.</p><p class="headingAnchor" id="H4352965"><span class="h3">Taxane desensitization</span><span class="headingEndMark"> — </span>For patients with recurrent infusion reactions despite premedication and a slower infusion rate, and for those with symptoms suggestive of anaphylaxis and positive skin test results, desensitization may allow continued taxane administration [<a href="#rid77">77,125</a>]. In one series, 17 patients with documented infusion reactions to taxanes who needed continued treatment underwent a desensitization similar to that used for the platinum drugs prior to each subsequent taxane dose  (<a class="graphic graphic_table graphicRef51577" href="/d/graphic/51577.html" rel="external">table 8</a>) [<a href="#rid125">125</a>]. Only five minor reactions were observed in 77 subsequent administrations. In another series, five patients were successfully desensitized with a protocol that began with a 1:100,000 dilution of the standard preparation [<a href="#rid77">77</a>]. The mechanism of "desensitization" in such cases is unclear since the vast majority of studied patients had negative skin tests to the taxanes.</p><p>Desensitization must be repeated each time the drug is given.</p><p class="headingAnchor" id="H3582085442"><span class="h2">Related agents</span><span class="headingEndMark"> — </span>Nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>) and <a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">cabazitaxel</a> are additional taxane preparations.</p><p class="headingAnchor" id="H41"><span class="h3">Nabpaclitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">Nabpaclitaxel</a> (Abraxane) does not use Cremophor as the vehicle. Infusion reactions have not been reported in phase I, II, or III studies of nabpaclitaxel, despite the omission of routine premedication [<a href="#rid126">126-128</a>]. In addition, this formulation can be administered over 30 minutes without the need for special tubing.</p><p>However, although the reported risk of an infusion reaction to <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> is lower than with solvent-based taxanes [<a href="#rid129">129</a>], one of the authors (MC) has seen two patients who developed severe infusion reactions involving back pain, dyspnea, and desaturation. Desensitization was not attempted because the diluent for Abraxane could not be obtained.</p><p><a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">Nabpaclitaxel</a> has also been used in patients who experienced paclitaxel-associated infusion reactions in the past [<a href="#rid130">130</a>], although one of the authors (MC) has seen several patients who were reactive to both <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and nabpaclitaxel. Thus, we do not recommend administering a full dose of nabpaclitaxel to patients with past infusion reactions to paclitaxel. Instead, we administer nabpaclitaxel to such patients in the following manner: We give one-tenth of the dose and wait 30 minutes, then one-fourth, one-half, and then the rest of the dose, with each step separated by 30-minute intervals. If this process is tolerated, then the patient can receive the next scheduled dose normally. (See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Taxanes'</a>.)</p><p class="headingAnchor" id="H3596554"><span class="h3">Cabazitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">Cabazitaxel</a>, a semisynthetic taxane derivative, has been associated with infusion reactions, especially during the first and second doses. Symptoms may include generalized rash/erythema, hypotension and bronchospasm. Premedication with a glucocorticoid and an H1 as well as H2 receptor antagonist is recommended prior to each dose to prevent infusion reactions.</p><p>The overall incidence of infusion reactions is unclear. In a phase I study of single agent <a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">cabazitaxel</a>, in which no patient received premedication, only 2 of 25 patients developed a grade 1 infusion reaction with flushing, dizziness and chest tightness; symptoms did not reoccur on retreatment despite the absence of premedication [<a href="#rid131">131</a>]. On the other hand, in a phase II study of 71 patients receiving single agent cabazitaxel, and premedicated only with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, four (6 percent) had an infusion reaction, three severe (grade 3 or 4) [<a href="#rid132">132</a>]. The phase III TROPIC trial of cabazitaxel in men with advanced prostate cancer utilized pretreatment with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg, as well as an H1 and H2 receptor blocker, and no infusion reactions were observed [<a href="#rid133">133</a>]. (See  <a class="medical medical_review" href="/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer", section on 'Men who have received prior docetaxel'</a>.)</p><p>It is unclear whether the infusions reactions seen with <a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">cabazitaxel</a> are attributable to the drug or its vehicle, polysorbate 80. The United States prescribing information lists reactions to other drugs containing polysorbate 80 (eg, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>) as a contraindication to use of cabazitaxel. The drug should be discontinued in the event of a severe reaction.</p><p class="headingAnchor" id="H42"><span class="h1">ANTHRACYCLINES AND RELATED AGENTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and characterization</strong> – Generalized infusion reactions are rare with free <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> but more common with liposomal anthracyclines. A localized skin reaction (flare) may develop around the infusion site, particularly after the first treatment, and usually does not cause generalized symptoms. It must be distinguished from drug extravasation. Premedication to prevent infusion related reactions is not recommended for either free doxorubicin, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, or other anthracycline-related agents. When they occur, recurrent reactions can be lessened by pretreatment with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and glucocorticoids, by reconstituting the drug in <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, and by limiting the initial infusion rate to ≤1 mg/min.</p><p></p><p class="bulletIndent1">Drugs of the anthracycline class (including <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> administered by the intravesical route [<a href="#rid134">134,135</a>]) and related agents rarely cause infusion reactions [<a href="#rid136">136</a>]. More often, a localized skin flare (erythema, pruritus, and localized urticaria at or adjacent to the site of drug administration) may follow the first intravenous (IV) infusion of anthracycline drugs, but it does not progress to a generalized reaction and anaphylaxis. Sometimes, this localized reaction may be confused with drug extravasation [<a href="#rid137">137</a>]. (See  <a class="medical medical_review" href="/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.)</p><p></p><p class="bulletIndent1">When infusion reactions occur, signs and symptoms may include flushing, dyspnea, facial edema, headache, chills, back pain, tightness of the chest or throat, presyncope, and hypotension [<a href="#rid12">12,136</a>].</p><p></p><p class="bulletIndent1">The incidence of generalized infusion reactions is higher with liposomal <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> and <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> (9 to 14 percent [<a href="#rid105">105,138</a>]) than with free drug. Infusion reactions to liposome-encapsulated formulations may involve a non-IgE-mediated mechanism, possibly directed against the liposomes [<a href="#rid139">139</a>]. Most reactions are mild, and symptoms resolve when the infusion rate is slowed; for this reason, the initial infusion rate should not exceed 1 mg/min. More severe reactions should be treated as possible anaphylaxis, including reactions that involve more than one organ system (eg, flushing and chest pain, hypotension and dyspnea, other combinations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premedication and prevention</strong> – Both the localized flare reaction and generalized infusion reaction can be successfully blocked by pretreatment with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and glucocorticoids [<a href="#rid140">140</a>]. Reconstitution of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> in <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> rather than distilled water seems to decrease the frequency of local flare reactions. (See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p></p><p class="bulletIndent1">Although data are limited, for severe reactions, desensitization using the same protocol employed for the platinum agents and taxanes was reported to be successful in six patients, despite negative skin tests  (<a class="graphic graphic_table graphicRef51577" href="/d/graphic/51577.html" rel="external">table 8</a>) [<a href="#rid12">12</a>]. Desensitization must be repeated each time the drug is given.</p><p></p><p class="headingAnchor" id="H45"><span class="h1">ASPARAGINASE</span><span class="headingEndMark"> — </span>Asparaginase, a polypeptide of bacterial origin, is an important component of treatment for acute lymphoblastic leukemia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations</strong> – There are currently five formulations of asparaginase: the original <em>Escherichia coli</em> (<em>E. coli</em>) asparaginase derivative (Elspar), which was discontinued in the United States in 2013 but is still available in Canada and elsewhere (Kidrolase); two other short-acting asparaginase products include bacterially derived <em>Erwinia chrysanthemi</em> asparaginase (Erwinase) and recombinant <em>Erwinia chrysanthemi</em> asparaginase (Rylaze), both of which can be used for patients with hypersensitivity to <em>E. coli</em>-derived asparaginase. Bacterially derived <em>Erwinia</em> <em>chrysanthemi</em> asparaginase is no longer available in the United States and Canada as of 2022, but remains available in the United Kingdom and the European Union.</p><p></p><p class="bulletIndent1">There are also two long-acting asparaginase products including <a class="drug drug_general" data-topicid="9745" href="/d/drug information/9745.html" rel="external">pegaspargase</a> (Oncaspar) and calaspargase (Asparlas), both of which are <em>E. coli</em>-derived. The pegylated products have longer half-lives (5 to 12 days [<a href="#rid141">141-143</a>] and 13 to 17 days [<a href="#rid143">143</a>], respectively). Pegaspargase has a more convenient schedule (eg, every 14 or 21 days instead of three times per week), is less expensive, and is most commonly used in treatment protocols for newly diagnosed patients. (See  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1">The half-life of asparaginase whether pegylated or not decreases precipitously in patients with anti-asparaginase antibodies (see below) [<a href="#rid144">144</a>].</p><p></p><p class="bulletIndent1">For patients who develop hypersensitivity to the <em>E. coli</em>-derived products, bacterially-derived Erwinia is costly, and there have been sporadic global shortages since 2017 [<a href="#rid145">145</a>]. These issues prompted the development of the recombinant formulation which was approved by the US Food and Drug Administration in July 2021 for individuals who have developed hypersensitivity to <em>E. coli</em>–derived asparaginase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infusion reactions</strong> – Hypersensitivity reactions with asparaginase range in severity from localized, transient erythema and rash at the site of injection to acute life-threatening anaphylaxis. The most common symptoms are pain, tenderness, swelling, and erythema at the injection site when given intramuscularly (IM), and dyspnea, bronchospasm, pruritus, skin rash, and urticaria when given intravenously (IV); uncommon symptoms include angioedema, laryngospasm, and hypotension [<a href="#rid10">10,146</a>]. Most reactions, usually following the second to fourth infusion, occur within minutes, but they can occur one to several hours after administration, or even later [<a href="#rid147">147</a>]. Delayed hypersensitivity reactions are more common with <a class="drug drug_general" data-topicid="9745" href="/d/drug information/9745.html" rel="external">pegaspargase</a> due to slow release of the primary antigen [<a href="#rid148">148</a>].</p><p></p><p class="bulletIndent1">Infusion reactions are more common with IV administration compared with IM or subcutaneous (SC) administration [<a href="#rid148">148-151</a>]. For this reason, the more immunogenic, nonpegylated forms are frequently given SC or IM, while the pegylated products are often given IV to minimize painful medication administration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incidence</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Nonpegylated products</strong> – The risk of a hypersensitivity reaction appears to be similar between the <em>E. coli</em>-derived products. Elspar was commonly used in the United States and has similar reaction rates to Kidrolase, the currently available asparaginase preparation. Prior to premedication, infusion rates ranged from 5 to 8 percent per administered dose, increasing with the number of doses; up to one-third or more of patients experience an infusion reaction by the fourth dose [<a href="#rid152">152-157</a>]. Fewer than 10 percent of reactions are "serious" (ie, accompanied by hypotension and/or respiratory distress).</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="17098" href="/d/drug information/17098.html" rel="external">Erwinia asparaginase</a> was developed for individuals with hypersensitivity to <em>E. coli</em>-derived asparaginase. However, infusion reactions can also occur. As an example, hypersensitivity reactions after the use of <a class="drug drug_general" data-topicid="132016" href="/d/drug information/132016.html" rel="external">recombinant Erwinia asparaginase</a> occurred in 25 percent of patients in clinical trials, although they were severe in only 2 percent [<a href="#rid158">158</a>]. For bacterially-derived Erwinia asparaginase, the rate of severe grade 3 or 4 reactions is approximately 5 percent [<a href="#rid159">159</a>]. The rate of other side effects (pancreatitis, thrombosis, etc) is approximately the same among all available forms of asparaginase.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pegylated products </strong>– Although <a class="drug drug_general" data-topicid="9745" href="/d/drug information/9745.html" rel="external">pegaspargase</a> is the least immunogenic of the available formulations and has a lower rate of severe reactions, less severe infusion reactions still occur in up to 30 percent of patients over the duration of therapy [<a href="#rid145">145,160-165</a>]. Similarly, with IV <a class="drug drug_general" data-topicid="120007" href="/d/drug information/120007.html" rel="external">calaspargase pegol</a>, grade 3 and 4 hypersensitivity reactions, including anaphylaxis, have been reported in 7 to 27 percent of patients [<a href="#rid143">143,165,166</a>]. All pegylated products are <em>E. coli</em>-derived.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mechanism</strong> – Patients who develop hypersensitivity reactions to <em>E. coli</em>-derived asparaginase can be shown to have developed antibodies against the drug. Both anti-asparaginase and anti-polyethylene glycol antibodies have been demonstrated [<a href="#rid167">167,168</a>]. The presence of these antibodies correlates to both the development of hypersensitivity reactions and to inactivation of the drug and loss of therapeutic effect. However, antidrug antibody levels are neither sensitive nor specific for loss of asparaginase activity [<a href="#rid169">169,170</a>]. Antidrug antibodies also have not correlated with survival if patients are switched to a different preparation of asparaginase after the allergic reaction [<a href="#rid146">146</a>]. Additionally, some patients without clinical hypersensitivity reactions develop drug-inactivating antibodies, a phenomenon commonly referred to as "<strong>silent inactivation</strong>" [<a href="#rid169">169</a>].</p><p></p><p class="bulletIndent2">Therapeutic drug monitoring (TDM) involves measuring the level of serum asparaginase directly. Trough serum asparaginase levels above 0.1 international units/mL assure sufficient asparaginase activity to be effective [<a href="#rid171">171</a>]. Institutions vary in their use of TDM. Some institutions, including that of one of the authors (TH), perform TDM for all patients receiving <em>E. coli</em>-derived asparaginase. Because the incidence of silent inactivation is low (&lt;2 percent), other sites choose to employ TDM only after an allergic reaction, particularly a grade 1/2 reaction of unclear etiology (late onset, atypical symptoms). Patients being treated with one of the pegylated asparaginase products who are shown to have low asparaginase levels can be switched to an Erwinia preparation, which results in improved outcomes [<a href="#rid172">172,173</a>]. It has wide interpatient variability, although the same threshold of &gt;0.1 international units/mL is considered effective [<a href="#rid171">171</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> – Many institutions have initiated universal premedication for all <em>E. coli</em>-derived asparaginase formulations including <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, an H1 blocker such as <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, and an H2 blocker (<a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a>), with or without a glucocorticoid, given 30 to 60 minutes before each asparaginase infusion or IM injection [<a href="#rid174">174</a>]. With universal premedication, the asparaginase reaction rate has fallen to less than 10 percent [<a href="#rid174">174</a>].</p><p></p><p class="bulletIndent2">This practice has not been widespread. However, in 2021 the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F103411s5201lbl.pdf&amp;token=axO4z1jTbE%2BEjm%2F21mW2fyv%2BbA6aekNvsZlUjjgHtg8YhDV2GaSAQFq1gmZYkbzinxU0%2BM9EV2NWRSsD3R3krimk5PrfZnh91x2EpxosoMI%3D&amp;TOPIC_ID=2835" target="_blank">pegaspargase United States Prescribing Information</a> was updated to recommend premedication of all patients with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, an H1-receptor blocker, and an H2-receptor blocker administered 30 to 60 minutes prior to each dose [<a href="#rid175">175</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F761102s008lbl.pdf&amp;token=2EHWCun16MaIeV8CAgxff4WLVeAIPmP3isBzGS4KDECSZnZq2lcg12INvzWi0izUHBYqOoz%2BLTtnqpLQxErJEzEK%2FNfJ7t48Om6vdXXuANM%3D&amp;TOPIC_ID=2835" target="_blank">label for calaspargase</a> has also been similarly updated to recommend routine premedication prior to each dose [<a href="#rid176">176</a>].</p><p></p><p class="bulletIndent2">Premedication is not required prior to <a class="drug drug_general" data-topicid="17098" href="/d/drug information/17098.html" rel="external">Erwinia asparaginase</a>, either the bacteria-derived or recombinant preparations. However, for patients with a prior history of anaphylaxis, it is often utilized, depending on the institution.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – Due to the high incidence of infusion reactions, asparaginase should only be administered in a facility that is capable of treating anaphylaxis if it occurs. The clinician must assume that each dose is capable of precipitating an infusion reaction and be prepared to deal with that possibility (ie, IV access and <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>, and <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> immediately available for use). General guidelines for immediate treatment of anaphylaxis in adults and children are outlined in the tables  (<a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Options for retreatment</strong> – For patients who develop a hypersensitivity reaction to one of the <em>E. coli</em>-derived pegylated asparaginase formulations, continued therapy is possible by switching to an Erwinia formulation [<a href="#rid153">153,155,172,177-179</a>]; cross-reactivity is unlikely with the <em>E. coli</em> and Erwinia derivatives of asparaginase because the two are antigenically distinct. The incidence rate of cross-reactivity is 3 to 33 percent [<a href="#rid171">171</a>]. Given the ongoing international shortage of bacterially-derived <a class="drug drug_general" data-topicid="17098" href="/d/drug information/17098.html" rel="external">Erwinia asparaginase</a>, strategies to minimize the need for it were developed [<a href="#rid145">145</a>]. These include universal premedication to minimize the number of patients developing hypersensitivity reactions to pegylated asparaginase products, and TDM to detect patients who have undergone silent inactivation [<a href="#rid174">174,180</a>].</p><p></p><p class="bulletIndent2">For patients who develop hypersensitivity reactions to pegylated asparaginase, TDM should be performed based on the severity of the reaction [<a href="#rid145">145,171</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For grade 1 and 2 reactions, monitor serum asparaginase activity three to seven days after asparaginase administration to identify inactivation and the need to switch to <a class="drug drug_general" data-topicid="17098" href="/d/drug information/17098.html" rel="external">Erwinia asparaginase</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For a grade 3 reaction, institutional policies vary. For a grade 4 reaction, switch to the Erwinia preparation, without definite need to check asparaginase activity.</p><p></p><p class="bulletIndent2">These issues have become less relevant with the availability of <a class="drug drug_general" data-topicid="132016" href="/d/drug information/132016.html" rel="external">recombinant Erwinia asparaginase</a>, but this drug is expensive and not yet widely available.</p><p></p><p class="bulletIndent2">Desensitization to <a class="drug drug_general" data-topicid="9745" href="/d/drug information/9745.html" rel="external">pegaspargase</a> is another option if a recombinant Erwinia preparation is not available or the patient also reacts to <a class="drug drug_general" data-topicid="17098" href="/d/drug information/17098.html" rel="external">Erwinia asparaginase</a> [<a href="#rid181">181,182</a>]. At least two small series have shown that it is possible to use a rapid desensitization protocol to allow the administration of pegaspargase, with subsequent levels of asparaginase above the threshold of 0.1 international units/mL. (See  <a class="medical medical_review" href="/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a>.)</p><p></p><p class="headingAnchor" id="H50"><span class="h1">BLEOMYCIN</span><span class="headingEndMark"> — </span>Several idiosyncratic reactions have been described in patients receiving <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, although most do not appear to be allergic in nature. Routine premedication to prevent these reactions is not usually recommended.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperpyrexia syndrome</strong> – Between 50 and 60 percent of patients receiving <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> have a self-limited mild febrile reaction without any other symptoms [<a href="#rid183">183</a>]. The incidence of fever decreases with subsequent doses, particularly if prophylactic antipyretics are administered.</p><p></p><p class="bulletIndent1">However, approximately 1 percent of patients receiving <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> (predominantly for lymphoma) develop a high fever followed by excessive sweating. This may be accompanied by wheezing, mental confusion, anuria, and hypotension. A small number of these patients progress to disseminated intravascular coagulation and die from this complication (fulminant hyperpyrexia) [<a href="#rid184">184-186</a>]. This idiosyncratic reaction may be immediate or delayed several hours to days following the dose. The incidence is highest after the first and second doses.</p><p></p><p class="bulletIndent1">In most cases, this syndrome appears to involve the release of pyrogenic cytokines and resembles the systemic inflammatory response syndrome (SIRS)  (<a class="graphic graphic_table graphicRef79464" href="/d/graphic/79464.html" rel="external">table 10</a>) more than a typical infusion reaction [<a href="#rid187">187</a>]. The observation that <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> did not induce histamine release, tachycardia, or hypotension in a dog model also argues against an IgE-mediated mechanism [<a href="#rid95">95</a>]. (See <a class="local">'Characteristics of reactions'</a> above and  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention and treatment</strong> – A test dose (intravenous [IV] injection of ≤2 units of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> followed by monitoring of vital signs every 15 minutes for a minimum of one hour) followed by administration of the remainder of the dose is recommended by the manufacturer prior to the first one to two doses of bleomycin in patients with lymphoma. However, many institutions (including that of the authors) do not do this because of the very low likelihood of a reaction, particularly after pretreatment with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>. Furthermore, whether a reaction to the test dose implies a contraindication to further bleomycin is unclear. Given that the reaction is almost always seen only after the first or second doses, successful rechallenge is usually possible with premedication.</p><p></p><p class="bulletIndent2">Anecdotal reports suggest that the hyperpyrexia syndrome can be treated with temporary drug discontinuation, hydration, glucocorticoids, antipyretics, and H1 receptor antagonists [<a href="#rid185">185</a>]. Treating preexisting fever with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> also may increase the patient's "margin" for tolerating drug-induced hyperpyrexia [<a href="#rid184">184</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity pneumonitis</strong> – Although <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> is more often associated with interstitial pneumonia and pulmonary fibrosis, it may cause acute hypersensitivity pneumonitis, presenting as dyspnea, cough, and rash. This syndrome is radiographically and clinically similar to the more common interstitial pneumonitis, except that it occurs at lower cumulative doses, is associated with peripheral eosinophilia, and lung biopsy is more consistent with a hypersensitivity reaction. Drug rechallenge has not consistently produced a recurrence of the syndrome, suggesting that it is not immune-mediated. (See  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute chest pain</strong> – Chest pain during infusion may represent another manifestation of acute <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity, although the mechanism appears to be an acute pleuropericarditis rather than an infusion reaction [<a href="#rid188">188</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other rare reactions</strong> – One fatal case of fulminant angioedema to <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> has been reported [<a href="#rid189">189</a>]. This reaction was preceded by eosinophilia, developed 48 hours after the end of a course of bleomycin, and involved angioedema and a generalized punctate, hemorrhagic rash that was not responsive to glucocorticoids.</p><p></p><p class="headingAnchor" id="H10520016"><span class="h1">CARFILZOMIB</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">Carfilzomib</a> is a second-generation proteasome inhibitor that is used in the treatment of relapsed/refractory multiple myeloma. It is administered once or twice weekly when given in combination with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, or twice weekly as monotherapy. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Proteasome inhibitors'</a> and  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Refractory to lenalidomide and daratumumab'</a>.)</p><p>Infusion-related reactions can include fever, chills, arthralgias, myalgias, facial flushing/edema, vomiting, weakness, dyspnea, hypotension, syncope, chest tightness, angina, and/or rigors; symptoms may develop immediately or be delayed up to 24 hours after drug administration. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F202714s029lbl.pdf&amp;token=XhGpbc%2BsIwhP0nz4sJC0vlNEWZ9Bhldv3Q8HiMQV8%2FxX%2FqKnT2WrflqX67keCGv1sdQ4BhrD0Icvg9BMsPPa30kFQlfx203tq5YQOVOoDxI%3D&amp;TOPIC_ID=2835" target="_blank">United States prescribing information</a> recommends that for combination antineoplastic regimens that include <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, the dexamethasone (either 20 or 40 mg, depending on the regimen schedule) be administered 30 minutes to 4 hours prior to each <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a> dose. For carfilzomib monotherapy, dexamethasone 4 or 8 mg (depending on the dosing regimen chosen for carfilzomib) should be administered orally or intravenously 30 minutes to 1 hour before each carfilzomib dose during the first cycle, and thereafter, as needed to help prevent infusion-related reactions. With this low-dose concomitant premedication, however, the incidence of fever and dyspnea during therapy is still high (19 to 28 percent in one phase II trial [<a href="#rid190">190</a>]).</p><p class="headingAnchor" id="H58"><span class="h1">CYTARABINE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and characteristics</strong> – Up to one-third of patients receiving <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> for acute myeloid leukemia (most of whom have had prior exposure to the drug) develop a characteristic "cytarabine syndrome" within 6 to 12 hours of drug infusion [<a href="#rid191">191-195</a>]. This flu-like syndrome consists of fever, rigors, diaphoresis, myalgias, arthralgias, conjunctivitis, a macular skin eruption, and occasionally, hypotension [<a href="#rid196">196</a>]. While the etiology is unclear, it is probably related to cytokine release rather than immune-mediated [<a href="#rid194">194,195</a>], although at least one study reports the presence of circulating immune complexes [<a href="#rid196">196</a>].</p><p></p><p class="bulletIndent1">In contrast, IgE-mediated reactions (anaphylaxis with angioedema, urticaria, hypotension) are reported rarely [<a href="#rid197">197-199</a>]. Patients with suggestive signs and symptoms should be referred to an allergist with experience in drug desensitization if continued therapy is indicated [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Other types of skin reactions are reported:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-related acral erythema (hand-foot syndrome) is characterized by intense, painful erythema predominantly involving the palms and soles, which may progress to bullae and desquamation. (See  <a class="medical medical_review" href="/d/html/142102.html" rel="external">"Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neutrophilic eccrine hidradenitis is another dermatologic condition that may represent a hypersensitivity reaction [<a href="#rid200">200</a>], although it is more likely the result of direct cutaneous drug toxicity. The characteristic skin lesions are erythematous plaques or nodules that may be tender or pruritic. (See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Neutrophilic eccrine hidradenitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and rechallenge</strong> – <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> is typically administered as a multiday regimen. (See  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent1">The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc4fdc56e-efd7-4825-a518-ef430b2b3df0&amp;token=8k1RTDjLO%2F%2BlVTQrB5rXpoAm4dPW8p1cClUd7oNtY0OYi8Mts2E3xthAMRNblzSWbyKQ5eoV22PgzgStjCD4uzIxELdJ2s51U%2Ftlww0N%2BDE5m8JdKWomqHEVmN78dsjA&amp;TOPIC_ID=2835" target="_blank">United States Prescribing Information for cytarabine</a> does not recommend premedication prior to each day's <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> dose. However, a dose of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> prior to and following each day's drug infusion may reduce the frequency of the cytarabine syndrome. Glucocorticoids may also be beneficial for both treatment and prevention of the cytarabine syndrome [<a href="#rid191">191,194</a>].</p><p></p><p class="bulletIndent1">Retreatment after <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> syndrome can usually be safely accomplished with increased premedication, even in patients with multiple reactions [<a href="#rid201">201,202</a>].</p><p></p><p class="headingAnchor" id="H61"><span class="h1">CYCLOPHOSPHAMIDE AND IFOSFAMIDE</span><span class="headingEndMark"> — </span>Premedication to prevent infusion reactions is not generally recommended with either <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>.</p><p><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> has rarely been associated with anaphylaxis [<a href="#rid203">203-206</a>]. The antigenic compound appears to be the active metabolite rather than the parent compound, which explains why reactions may develop up to 16 hours after drug administration [<a href="#rid205">205</a>].</p><p>Infusion reactions are also reported with <a class="drug drug_general" data-topicid="9615" href="/d/drug information/9615.html" rel="external">MESNA</a>, which may be given with high-dose regimens to prevent hemorrhagic cystitis [<a href="#rid206">206,207</a>]. A desensitization protocol was effective one case report [<a href="#rid205">205</a>].</p><p><a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a> is rarely reported to cause anaphylaxis; in all cases, it was given with <a class="drug drug_general" data-topicid="9615" href="/d/drug information/9615.html" rel="external">MESNA</a> [<a href="#rid208">208,209</a>].</p><p class="headingAnchor" id="H64"><span class="h1">ETOPOSIDE</span><span class="headingEndMark"> — </span>Approximately 1 to 3 percent of patients who receive intravenous (IV) <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> develop angioedema, chest discomfort, bronchospasm, and/or hypotension, usually within minutes of starting the drug infusion [<a href="#rid210">210,211</a>]. Although the mechanism is unclear, the clinical pattern is consistent with anaphylaxis.</p><p>The reaction is thought due to the vehicle rather than the drug. The vehicle, polysorbate-80, is the same as that used for <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (see <a class="local">'Mechanisms of infusion reactions'</a> above). Additional support for this hypothesis is provided by the lack of allergic reactions in patients receiving oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, which does not contain polysorbate-80. However, there are at least two case reports of hypersensitivity reactions with an alternative formulation of etoposide, <a class="drug drug_general" data-topicid="8431" href="/d/drug information/8431.html" rel="external">etoposide phosphate</a>, which does not contain polysorbate-80 [<a href="#rid212">212</a>].</p><p>Premedication to prevent infusion reactions is not routinely recommended prior to IV <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>. When it occurs, etoposide hypersensitivity may be managed by pretreatment with a glucocorticoid and antihistamines [<a href="#rid200">200,213</a>], several reports indicate that switching to <a class="drug drug_general" data-topicid="8431" href="/d/drug information/8431.html" rel="external">etoposide phosphate</a> is safe in patients who develop an infusion reaction with IV etoposide [<a href="#rid214">214,215</a>].</p><p class="headingAnchor" id="H65"><span class="h1">IXABEPILONE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">Ixabepilone</a> is a microtubule inhibitor in the epothilone class that has been approved for treatment of patients with metastatic breast cancer. Like <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, it is formulated in Cremophor. </p><p>Infusion reactions, including anaphylaxis, are reported in approximately 1 percent of patients. <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">Ixabepilone</a> is <strong>contraindicated</strong> in patients with prior reactions to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> in Cremophor. As with the taxanes, treatment with ixabepilone requires premedication with H1 as well as H2 receptor antagonists approximately one hour prior to chemotherapy administration. (See <a class="local">'Premedication regimens'</a> above.)</p><p>Patients who experience a hypersensitivity reaction despite antihistamines require the addition of corticosteroids (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 20 mg intravenously 30 minutes before infusion, or orally 60 minutes before infusion) to the premedication regimen. Notably, if dexamethasone, a strong cytochrome P450 3A4 (CYP3A4) inducer, is used, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D241f0b1e-8b95-470d-876f-bf1804daaf18&amp;token=Jr8qSi%2F7FAA3hICspFoHbXHnwJvbhbwUGCSFLU2Qskq3HUo33nixqLTZZ%2FkfBe6JgjxPA3BB%2FltdAFr2%2B9C8rHNOvuFFxWpczwvjy3ZU6WUGWNWUrwcecAQdz9EGaKWZ&amp;TOPIC_ID=2835" target="_blank">United States Prescribing Information for ixabepilone</a> recommends adjusting the <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a> dose gradually up to 60 mg/m<sup>2</sup> (as a four-hour infusion), with careful monitoring. If the dexamethasone is discontinued, reduce the ixabepilone dose to the dose used prior to initiation of dexamethasone.</p><p class="headingAnchor" id="H368312859"><span class="h1">LEUCOVORIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">Leucovorin</a> is commonly administered simultaneously with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> for the treatment of gastric and colorectal cancers, in regimens such as <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) plus leucovorin and short-term infusional oxaliplatin (ie, FOLFOX) or FU plus leucovorin and irinotecan (ie, FOLFIRI).</p><p>As noted above, some patients who develop infusion reactions during administration of these regimens are commonly presumed to be reacting to <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. However, some of these reactions represent hypersensitivity to <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>. (See <a class="local">'Oxaliplatin'</a> above.)</p><p>Infusion reactions due to <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> appear to be rare, although they may be under-recognized and mistakenly attributed to a co-administered agent, particularly <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid216">216,217</a>]. In the largest series of five patients, symptoms appeared 10 to 70 minutes after the start of the combined-drug infusions and included facial erythema, urticaria, itching, angioedema, dyspnea, and chest pain [<a href="#rid217">217</a>]. These five patients were derived from a cohort of 44 patients who were assessed after suffering a hypersensitivity reaction to a chemotherapy regimen containing leucovorin (35 FOLFOX and 9 FOLFIRI). Four were receiving FOLFOX, and one, FOLFIRI. One patient had chills, fever, back pain, and elevated blood pressure. Two patients reacted to the first administered dose, while the others had received repeated doses prior to reacting. The mechanism(s) underlying these infusion reactions is not known. Skin testing was performed, although it was not positive in any of the five patients, and the diagnosis was made with leucovorin provocation, which reproduced the symptoms.</p><p>These reactions have all occurred in patients receiving racemic (D,L) <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, the most commonly used formulation. Given the lack of published reports of hypersensitivity to the L-isomer of leucovorin (<a class="drug drug_general" data-topicid="10324" href="/d/drug information/10324.html" rel="external">LEVOleucovorin</a>) three of the five patients described above who had presumed hypersensitivity reactions to racemic leucovorin during FOLFOX or FOLFIRI chemotherapy were subsequently challenged with LEVOleucovorin and also reacted, suggesting a high rate of cross-reactivity [<a href="#rid217">217</a>]. One patient opted to continue leucovorin using a rapid desensitization protocol, which allowed FOLFIRI to be continued without recurrent symptoms. The desensitization protocol used is described elsewhere. (See  <a class="medical medical_review" href="/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a>.)</p><p class="headingAnchor" id="H66"><span class="h1">METHOTREXATE AND PEMETREXED</span><span class="headingEndMark"> — </span>Infusion reactions to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> are rare [<a href="#rid218">218</a>]. Premedication is not routinely recommended prior to each dose. Patients who develop recurrent reactions for whom other therapeutic options are not available may benefit from a desensitization protocol [<a href="#rid219">219-221</a>].</p><p>Infusion reactions are also rare with <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, although at least one case of urticarial vasculitis has been reported [<a href="#rid222">222</a>]. Early studies noted a high rate of maculopapular skin rash with pemetrexed (15 percent overall, severe in approximately 1 percent). Both the incidence and severity of skin rash have been reduced with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> premedication. (See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Exanthematous (maculopapular) eruptions'</a>.)</p><p class="headingAnchor" id="H70"><span class="h1">TEMSIROLIMUS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> is a specific inhibitor of the mammalian target of rapamycin (mTOR) and is the first agent of this drug class to be used clinically for the treatment of renal cell cancer (RCC). (See  <a class="medical medical_review" href="/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"</a>.)</p><p>Although allergic reactions are described, their nature and severity are poorly documented [<a href="#rid223">223-225</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II trial of <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> as a single agent in advanced RCC, six patients (8 percent) had an "allergic reaction" but the specific symptoms, severity, and management were not described [<a href="#rid223">223</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The final report of a phase III trial compared <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> versus interferon versus both drugs in the treatment of advanced RCC did not note any grade 3 or 4 allergic reactions in patients receiving temsirolimus [<a href="#rid224">224</a>]. However, unpublished observations indicate that 5 percent of patients had an allergic reaction, none severe [<a href="#rid225">225</a>]. Reported symptoms were flushing, sensation of warmth, and headache.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The United States prescribing information also lists anaphylaxis, dyspnea, and chest discomfort as potential symptoms of an allergic reaction, but does not specify their incidence or severity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reactions may be attributed to the drug or its vehicle, polysorbate 80, an agent that has been associated with infusion reactions with other drugs (<a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>).</p><p></p><p>The manufacturer recommends pretreatment with an H1 receptor blocker (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>) before the start of each infusion and avoidance of <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> in patients who have had a history of hypersensitivity to the related drug <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>. </p><p>Guidelines for management of an infusion reaction include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Stop the infusion and observe the patient for at least 30 to 60 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the clinician's discretion, treatment may be resumed with the administration of an H1 receptor antagonist, if not previously administered, and/or an H2 receptor blocker (intravenous <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 20 mg) approximately 30 minutes before restarting the infusion. The infusion may be resumed at a slower rate (up to 60 minutes).</p><p></p><p class="headingAnchor" id="H71"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General aspects</strong> – Virtually all chemotherapeutic agents have the potential to initiate infusion reactions. Certain drugs (eg, platinum agents and taxanes) are associated with anaphylaxis, which arises from sudden and widespread activation of mast cells and/or basophils. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Infusion reactions range in severity from mild pruritus and flushing to life-threatening hypotension and bronchospasm. Most are mild and occur during or within one hour of drug administration. (See <a class="local">'Characteristics of reactions'</a> above.)</p><p></p><p class="bulletIndent1">The National Cancer Institute (NCI) system of classifying infusion reactions is based on severity  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>). However, allergists emphasize the differentiation of anaphylaxis from all other types of standard infusion reactions (SIRs). Although there is some overlap, characteristic symptoms of anaphylaxis include urticaria, wheezing, hypotension, and gastrointestinal symptoms, but not fever. Anaphylaxis is likely to recur despite premedication and can typically become more severe upon re-exposure, regardless of the severity of the initial symptoms. (See <a class="local">'Classification of infusion reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Premedication can help prevent and/or reduce the severity of infusion reactions, although it is not effective in preventing anaphylaxis. Specific premedication regimens for individual agents are addressed in the individual sections above. (See <a class="local">'Use of premedication to prevent infusion reactions'</a> above.)</p><p></p><p class="bulletIndent1">The role of skin testing to screen patients before they develop an infusion reaction remains uncertain, and most institutions do not routinely perform them. (See <a class="local">'Skin testing'</a> above and <a class="local">'Retreatment after an infusion reaction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate treatment</strong> – Despite the use of premedication, clinicians must be prepared for an infusion reaction to occur during each drug administration. Standing orders should be in place to allow immediate intervention without waiting for the clinician to arrive. Medical equipment and supplies needed for resuscitation should be readily available. (See <a class="local">'Principles of treatment and rechallenge'</a> above.)</p><p></p><p class="bulletIndent1">Immediate management is tailored to the clinical situation. The following represent general guidelines for management of a patient who is suspected of having an infusion reaction to a chemotherapeutic agent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate reaction</strong> – If the reaction is limited to mild or moderate symptoms of SIR (grades 1 or 2  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)), without features suggestive of anaphylaxis, drug infusion should be temporarily stopped and assessment of airway, breathing, circulation, and mentation accomplished rapidly. Intravenous (IV) administration of 50 mg of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> may provide symptomatic relief. Once symptoms have resolved, resumption of the drug infusion at a slowed rate may permit treatment continuation with close monitoring.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe reaction or anaphylaxis</strong> – Severe SIRs (grades 3 or 4  (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 1</a>)) or reactions with any features of anaphylaxis (eg, generalized urticaria, wheezing, hypotension, and angioedema) require prompt recognition and treatment. In fatal anaphylaxis, death typically ensues within 30 minutes from exposure to the trigger. (See <a class="local">'Treatment of anaphylaxis and severe standard infusion reactions'</a> above.)</p><p></p><p class="bulletIndent2">Initial management of anaphylaxis is summarized in a rapid overview table for adults  (<a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 4</a>) and children  (<a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 5</a>) is covered in detail elsewhere and includes the following (see  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Immediately discontinue drug infusion</p><p class="bulletIndent3"><span class="glyph">-</span>Place the patient in the supine position with legs elevated (if tolerated)</p><p class="bulletIndent3"><span class="glyph">-</span>Assess airway, breathing, circulation, and adequacy of mentation</p><p class="bulletIndent3"><span class="glyph">-</span>Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)</p><p class="bulletIndent3"><span class="glyph">-</span>Administer intramuscular <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> into the anterolateral thigh (0.3 to 0.5 mg aqueous epinephrine, 1:1000 dilution)</p><p class="bulletIndent3"><span class="glyph">-</span>Establish IV access with two 14 to 16 gauge catheters</p><p class="bulletIndent3"><span class="glyph">-</span>Administer both an H1 (eg, 50 mg of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>) and an H2 (eg, 20 mg of <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a>) antihistamine IV</p><p class="bulletIndent3"><span class="glyph">-</span>Systemic administration of a glucocorticoid (eg, 40 to 80 mg <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> IV) may not help acutely, although it may prevent a prolonged or recurrent reaction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rechallenge</strong> – The decision to attempt retreatment after resolution of the acute event depends upon the specific drug, the severity of the reaction, the cancer being treated and the intent of treatment (ie, potentially curative or palliative), and whether there are reasonable treatment alternatives:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most drugs, if the reaction was mild or moderate (NCI grades 1 or 2) <strong>and lacking</strong> signs or symptoms to suggest anaphylaxis, rechallenge is often possible with premedication (glucocorticoids, antihistamines) and a slower rate of infusion. <strong>However, for patients treated with a platinum agent, retreatment should not be attempted, even with additional premedications. Instead, we suggest referral to an allergy or oncology center with experience in drug desensitization.</strong> (see <a class="local">'Principles of treatment and rechallenge'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For severe SIRs (NCI grade 3 or higher) and any reactions with symptoms of anaphylaxis, retreatment should not be attempted. Instead, we suggest referral to an allergy or oncology center with experience in drug desensitization [<a href="#rid34">34,186</a>]. (See <a class="local">'Anaphylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin testing may be helpful in the evaluation of SIRs, especially with the platinum drugs and taxanes. If skin testing is positive, then the patient should not be rechallenged. If there is no equivalent substitute drug, then such patients should be given that medication only through desensitization in the future. The negative predictive value of skin testing with platinum drugs and taxanes is high, and patients with a negative result can receive the drug again using a graded challenge. (See <a class="local">'Overview of skin testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Desensitization</strong> – Desensitization protocols have been developed at centers with expertise in drug allergy, and they have been most successfully applied to taxanes and platinum drugs. However, experience with desensitization is not widespread, and the success of these protocols in other settings has not been reported. (See <a class="local">'Platinum drugs'</a> above and <a class="local">'Taxanes'</a> above.)</p><p></p><p class="bulletIndent1">Desensitization should only be carried out under close medical supervision by experienced individuals who are prepared to deal with emergency management of anaphylaxis. Most, if not all desensitization protocols are performed by allergists. Desensitization must be repeated each time the patient requires the drug in the future. (See <a class="local">'Overview of desensitization'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141.</a></li><li><a class="nounderline abstract_t">Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5:309.</a></li><li class="breakAll">Academic centers in the United States and Europe with departments of Allergy and Immunology are likely to have such experience. In the United States, these centers include Brigham and Women's Hospital, John's Hopkins, the Mayo Clinic, Massachusetts General Hospital, National Institutes of Health, University of California and Los Angeles, Scripps Clinic, and University of Texas (Southwestern Medical Center).</li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.</a></li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.</a></li><li><a class="nounderline abstract_t">A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc 2011; 32:79.</a></li><li><a class="nounderline abstract_t">Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol 2017; 140:321.</a></li><li><a class="nounderline abstract_t">Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.</a></li><li><a class="nounderline abstract_t">Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215.</a></li><li><a class="nounderline abstract_t">Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12:601.</a></li><li><a class="nounderline abstract_t">2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV.</a></li><li><a class="nounderline abstract_t">Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.</a></li><li><a class="nounderline abstract_t">Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004; 130:25.</a></li><li><a class="nounderline abstract_t">Pradelli J, Verdoire P, Boutros J, et al. Allergy Evaluation of Hypersensitivity to Platinum Salts and Taxanes: A Six-Year Experience. J Allergy Clin Immunol Pract 2020; 8:1658.</a></li><li><a class="nounderline abstract_t">Gastaminza G, de la Borbolla JM, Goikoetxea MJ, et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 2011; 21:108.</a></li><li><a class="nounderline abstract_t">Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract 2016; 4:497.</a></li><li><a class="nounderline abstract_t">Cinollo G, Dini G, Franchini E, et al. Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin. Cancer Chemother Pharmacol 1988; 21:85.</a></li><li><a class="nounderline abstract_t">Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996; 36:1016.</a></li><li><a class="nounderline abstract_t">Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97:2301.</a></li><li><a class="nounderline abstract_t">Desrame J, Broustet H, Darodes de Tailly P, et al. Oxaliplatin-induced haemolytic anaemia. Lancet 1999; 354:1179.</a></li><li><a class="nounderline abstract_t">de Vries RS, Mattijssen EJ, van Sorge AA. Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006; 17:1723.</a></li><li><a class="nounderline abstract_t">Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin Colorectal Cancer 2005; 5:283.</a></li><li><a class="nounderline abstract_t">Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20:1146.</a></li><li><a class="nounderline abstract_t">Polyzos A, Tsavaris N, Gogas H, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009; 76:36.</a></li><li><a class="nounderline abstract_t">Wong JT, Ling M, Patil S, et al. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2014; 2:40.</a></li><li><a class="nounderline abstract_t">Suenaga M, Mizunuma N, Shinozaki E, et al. Management of allergic reactions to oxaliplatin in colorectal cancer patients. J Support Oncol 2008; 6:373.</a></li><li><a class="nounderline abstract_t">Kidera Y, Satoh T, Ueda S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 2011; 16:244.</a></li><li><a class="nounderline abstract_t">Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61:129.</a></li><li><a class="nounderline abstract_t">Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370.</a></li><li><a class="nounderline abstract_t">Banerji A, Lax T, Guyer A, et al. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2014; 2:428.</a></li><li><a class="nounderline abstract_t">Gadducci A, Tana R, Teti G, et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18:615.</a></li><li><a class="nounderline abstract_t">Cheng E, Cvitkovic E, Wittes RE, Golbey RB. Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer 1978; 42:2162.</a></li><li><a class="nounderline abstract_t">Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95:414.</a></li><li><a class="nounderline abstract_t">Robinson JB, Singh D, Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82:550.</a></li><li><a class="nounderline abstract_t">Koren C, Yerushalmi R, Katz A, et al. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 2002; 25:625.</a></li><li><a class="nounderline abstract_t">Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212.</a></li><li><a class="nounderline abstract_t">Lafay-Cousin L, Sung L, Carret AS, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer 2008; 112:892.</a></li><li><a class="nounderline abstract_t">Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103:608.</a></li><li><a class="nounderline abstract_t">O'Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol 2010; 116:326.</a></li><li><a class="nounderline abstract_t">Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013; 109:1072.</a></li><li><a class="nounderline abstract_t">Altwerger G, Florsheim EB, Menderes G, et al. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. J Cancer Res Clin Oncol 2018; 144:2449.</a></li><li><a class="nounderline abstract_t">Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006; 17:259.</a></li><li><a class="nounderline abstract_t">Lee MY, Yang MH, Liu JH, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007; 15:89.</a></li><li><a class="nounderline abstract_t">Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009; 76:231.</a></li><li><a class="nounderline abstract_t">Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003; 89:477.</a></li><li><a class="nounderline abstract_t">Gowda A, Goel R, Berdzik J, et al. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004; 18:1671.</a></li><li class="breakAll">Kim BH, Bradley TP, Tai JY, Budman DR. Five-year analysis of hypersensitivity reactions to oxaliplatin: Determination of incidence and identification of risk factors (abstract). J Clin Oncol 2008; 26:121s.</li><li><a class="nounderline abstract_t">Ulusakarya A, Misra S, Haydar M, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 2010; 27:1425.</a></li><li><a class="nounderline abstract_t">Bencardino K, Mauri G, Amatu A, et al. Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clin Colorectal Cancer 2016; 15:213.</a></li><li><a class="nounderline abstract_t">Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res 2008; 28:3115.</a></li><li><a class="nounderline abstract_t">Baretta Z, Falci C, Piva E, Conte P. Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report. Clin Colorectal Cancer 2013; 12:294.</a></li><li><a class="nounderline abstract_t">Teng CJ, Hsieh YY, Chen KW, et al. Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review. Jpn J Clin Oncol 2011; 41:125.</a></li><li><a class="nounderline abstract_t">Bergamini A, Pisano C, Di Napoli M, et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol 2017; 144:72.</a></li><li><a class="nounderline abstract_t">Caiado J, Venemalm L, Pereira-Santos MC, et al. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 2013; 1:494.</a></li><li><a class="nounderline abstract_t">Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84:378.</a></li><li><a class="nounderline abstract_t">Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53:121.</a></li><li><a class="nounderline abstract_t">Herrero T, Tornero P, Infante S, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 2006; 16:327.</a></li><li><a class="nounderline abstract_t">Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19:3126.</a></li><li><a class="nounderline abstract_t">Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21:4611.</a></li><li><a class="nounderline abstract_t">Leguy-Seguin V, Jolimoy G, Coudert B, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007; 119:726.</a></li><li><a class="nounderline abstract_t">Pagani M, Bonadonna P, Senna GE, Antico A. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 2008; 145:54.</a></li><li><a class="nounderline abstract_t">Gomez R, Harter P, Lück HJ, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 2009; 19:1284.</a></li><li><a class="nounderline abstract_t">Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99:393.</a></li><li><a class="nounderline abstract_t">Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003; 14:497.</a></li><li><a class="nounderline abstract_t">Hesterberg PE, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009; 123:1262.</a></li><li><a class="nounderline abstract_t">Lax T, Long A, Banerji A. Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions. J Allergy Clin Immunol Pract 2015; 3:856.</a></li><li><a class="nounderline abstract_t">Patil SU, Long AA, Ling M, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 2012; 129:443.</a></li><li><a class="nounderline abstract_t">Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, et al. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy 2015; 70:784.</a></li><li><a class="nounderline abstract_t">Rose PG, Fusco N, Smrekar M, et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 2003; 89:429.</a></li><li><a class="nounderline abstract_t">Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26:105.</a></li><li><a class="nounderline abstract_t">Altwerger G, Gressel GM, English DP, et al. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecol Oncol 2017; 144:77.</a></li><li><a class="nounderline abstract_t">Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol 2004; 93:137.</a></li><li><a class="nounderline abstract_t">Rosique-Robles D, Vicent Verge JM, Borrás-Blasco J, et al. Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin. Int J Clin Pharmacol Ther 2007; 45:606.</a></li><li><a class="nounderline abstract_t">Rassy E, Le Roy F, Smolenschi C, et al. Rechallenge After Oxaliplatin-Induced Hypersensitivity Reactions. JAMA Oncol 2023; 9:434.</a></li><li><a class="nounderline abstract_t">Pasteur J, Favier L, Pernot C, et al. Low Cross-Reactivity Between Cisplatin and Other Platinum Salts. J Allergy Clin Immunol Pract 2019; 7:1894.</a></li><li class="breakAll">Mariana Castells, MD PhD, personal communication.</li><li><a class="nounderline abstract_t">Syrigou E, Dannos I, Kotteas E, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011; 156:320.</a></li><li><a class="nounderline abstract_t">Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19:458.</a></li><li><a class="nounderline abstract_t">Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 2016; 137:1154.</a></li><li><a class="nounderline abstract_t">Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47:2486.</a></li><li><a class="nounderline abstract_t">Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27:347.</a></li><li><a class="nounderline abstract_t">Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14:422.</a></li><li><a class="nounderline abstract_t">Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002; 84:420.</a></li><li><a class="nounderline abstract_t">Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654.</a></li><li><a class="nounderline abstract_t">Tsavaris NB, Kosmas C. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharmacol 1998; 42:509.</a></li><li><a class="nounderline abstract_t">Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4:610.</a></li><li><a class="nounderline abstract_t">Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002; 70:329.</a></li><li><a class="nounderline abstract_t">Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85:1247.</a></li><li><a class="nounderline abstract_t">Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002; 23:205.</a></li><li><a class="nounderline abstract_t">Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004; 15:581.</a></li><li><a class="nounderline abstract_t">Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263.</a></li><li><a class="nounderline abstract_t">Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90:300.</a></li><li><a class="nounderline abstract_t">Liau-Chu M, Theis JG, Koren G. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine. Ann Pharmacother 1997; 31:1287.</a></li><li><a class="nounderline abstract_t">Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:1238.</a></li><li><a class="nounderline abstract_t">Eschalier A, Lavarenne J, Burtin C, et al. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988; 21:246.</a></li><li><a class="nounderline abstract_t">Prieto García A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 2010; 20:170.</a></li><li><a class="nounderline abstract_t">Essayan DM, Kagey-Sobotka A, Colarusso PJ, et al. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996; 97:42.</a></li><li><a class="nounderline abstract_t">Fujimori K, Yokoyama A, Kurita Y, et al. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55:340.</a></li><li><a class="nounderline abstract_t">Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426.</a></li><li><a class="nounderline abstract_t">Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149.</a></li><li><a class="nounderline abstract_t">Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996; 7 Suppl 2:25.</a></li><li><a class="nounderline abstract_t">Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131:202.</a></li><li><a class="nounderline abstract_t">Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90:304.</a></li><li><a class="nounderline abstract_t">Bookman MA, Kloth DD, Kover PE, et al. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol 1997; 24:S19.</a></li><li><a class="nounderline abstract_t">Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24:253.</a></li><li><a class="nounderline abstract_t">Yahata H, Saito M, Sendo T, et al. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int J Cancer 2006; 118:2636.</a></li><li><a class="nounderline abstract_t">Cox JM, van Doorn L, Malmberg R, et al. The added value of H2 antagonists in premedication regimens during paclitaxel treatment. Br J Cancer 2021; 124:1647.</a></li><li><a class="nounderline abstract_t">Gennari A, Salvadori B, Tognoni A, Conte PF. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 1996; 7:978.</a></li><li><a class="nounderline abstract_t">Markman M, Kennedy A, Webster K, et al. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol 1997; 15:3517.</a></li><li><a class="nounderline abstract_t">Bookman MA, Kloth DD, Kover PE, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997; 8:611.</a></li><li><a class="nounderline abstract_t">Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002; 41:418.</a></li><li><a class="nounderline abstract_t">Lansinger OM, Biedermann S, He Z, Colevas AD. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. J Clin Oncol 2021; 39:3583.</a></li><li><a class="nounderline abstract_t">Chen FC, Wang LH, Zheng XY, et al. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions. Oncotarget 2017; 8:19236.</a></li><li><a class="nounderline abstract_t">Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353.</a></li><li><a class="nounderline abstract_t">Quock J, Dea G, Tanaka M, et al. Premedication strategy for weekly paclitaxel. Cancer Invest 2002; 20:666.</a></li><li><a class="nounderline abstract_t">Berger MJ, Vargo C, Vincent M, et al. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2015; 23:2019.</a></li><li><a class="nounderline abstract_t">Parinyanitikul N, Tanpipattanakul W, Poovorawan N, et al. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. Support Care Cancer 2018; 26:2471.</a></li><li><a class="nounderline abstract_t">Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004; 9:538.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89:328.</a></li><li><a class="nounderline abstract_t">Stemmler J, Mair W, Stauch M, et al. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 2005; 68:71.</a></li><li><a class="nounderline abstract_t">Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.</a></li><li><a class="nounderline abstract_t">Krieger JA, Stanford BL, Ballard EE, Rabinowitz I. Implementation and results of a test dose program with taxanes. Cancer J 2002; 8:337.</a></li><li><a class="nounderline abstract_t">Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11:885.</a></li><li><a class="nounderline abstract_t">Laskin MS, Lucchesi KJ, Morgan M. Paclitaxel rechallenge failure after a major hypersensitivity reaction. J Clin Oncol 1993; 11:2456.</a></li><li><a class="nounderline abstract_t">Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96:824.</a></li><li><a class="nounderline abstract_t">Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8:1038.</a></li><li><a class="nounderline abstract_t">Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23:6019.</a></li><li><a class="nounderline abstract_t">Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794.</a></li><li><a class="nounderline abstract_t">He F, Liu J, Shen X, et al. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Ann Pharmacother 2022; 56:898.</a></li><li><a class="nounderline abstract_t">Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 2009; 19:1281.</a></li><li><a class="nounderline abstract_t">Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723.</a></li><li><a class="nounderline abstract_t">Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547.</a></li><li><a class="nounderline abstract_t">de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.</a></li><li><a class="nounderline abstract_t">Birch BR, Crisp JC. Allergic reaction to intravesical adriamycin. Br J Urol 1988; 61:165.</a></li><li><a class="nounderline abstract_t">Crawford ED, McKenzie D, Mansson W, et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. J Urol 1986; 136:668.</a></li><li><a class="nounderline abstract_t">Solimando DA Jr, Wilson JP. Doxorubicin-induced hypersensitivity reactions. Drug Intell Clin Pharm 1984; 18:808.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ. "Adriamycin flare": a skin reaction resembling extravasation. Cancer Treat Rep 1979; 63:2067.</a></li><li><a class="nounderline abstract_t">Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54 Suppl 4:30.</a></li><li><a class="nounderline abstract_t">Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14:1430.</a></li><li><a class="nounderline abstract_t">Rahman A, Treat J, Roh JK, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990; 8:1093.</a></li><li><a class="nounderline abstract_t">Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457:621.</a></li><li><a class="nounderline abstract_t">Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109:2744.</a></li><li><a class="nounderline abstract_t">Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol 2014; 32:3874.</a></li><li><a class="nounderline abstract_t">Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma 2016; 57:748.</a></li><li><a class="nounderline abstract_t">Marini BL, Brown J, Benitez L, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma 2019; 60:2854.</a></li><li><a class="nounderline abstract_t">Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18:1525.</a></li><li><a class="nounderline abstract_t">Spiegel RJ, Echelberger CK, Poplack DG. Delayed allergic reactions following intramuscular L-asparaginase. Med Pediatr Oncol 1980; 8:123.</a></li><li><a class="nounderline abstract_t">Petersen WC Jr, Clark D, Senn SL, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2014; 31:311.</a></li><li><a class="nounderline abstract_t">Abbott LS, Zakova M, Shaikh F, et al. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review. Paediatr Drugs 2015; 17:315.</a></li><li><a class="nounderline abstract_t">Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma 2018; 59:1624.</a></li><li><a class="nounderline abstract_t">Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979; 1:9.</a></li><li><a class="nounderline abstract_t">Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008; 8:56.</a></li><li><a class="nounderline abstract_t">Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982; 49:1378.</a></li><li><a class="nounderline abstract_t">Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977; 3:387.</a></li><li><a class="nounderline abstract_t">Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12:660.</a></li><li><a class="nounderline abstract_t">Kurtzberg J, Asselin B, Bernstein M, et al. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol 2011; 33:610.</a></li><li><a class="nounderline abstract_t">Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol 2015; 16:1677.</a></li><li class="breakAll">US Prescribing information for recombinant Erwinia asparaginase available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761179s000lbl.pdf (Accessed on July 12, 2021).</li><li class="breakAll">US prescribing information for Erwinia asparaginase available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125359s098lbl.pdf (Accessed on July 12, 2021).</li><li><a class="nounderline abstract_t">Chang A, Kim M, Seyer M, Patel S. Allergic reactions associated with pegaspargase in adults. Leuk Lymphoma 2016; 57:1665.</a></li><li><a class="nounderline abstract_t">Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338:1663.</a></li><li><a class="nounderline abstract_t">Graham ML, Asselin BL, Herndon JE 2nd, et al. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21:879.</a></li><li><a class="nounderline abstract_t">Ettinger LJ, Kurtzberg J, Voûte PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995; 75:1176.</a></li><li><a class="nounderline abstract_t">Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 2014; 32:905.</a></li><li><a class="nounderline abstract_t">Vrooman LM, Blonquist TM, Stevenson KE, et al. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol 2021; 39:3496.</a></li><li class="breakAll">US prescribing information for calaspargase pegol-mknl available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761102s000lbl.pdf (Accessed on January 15, 2019).</li><li><a class="nounderline abstract_t">Liu Y, Smith CA, Panetta JC, et al. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol 2019; 37:2051.</a></li><li><a class="nounderline abstract_t">Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007; 110:103.</a></li><li><a class="nounderline abstract_t">Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012; 26:2303.</a></li><li><a class="nounderline abstract_t">Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12:1527.</a></li><li><a class="nounderline abstract_t">van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 2016; 101:279.</a></li><li><a class="nounderline abstract_t">Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014; 123:2026.</a></li><li><a class="nounderline abstract_t">Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31:1202.</a></li><li><a class="nounderline abstract_t">Cooper SL, Young DJ, Bowen CJ, et al. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer 2019; 66:e27797.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103411s5201lbl.pdf (Accessed on January 04, 2022).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761102s008lbl.pdf (Accessed on January 04, 2022).</li><li><a class="nounderline abstract_t">Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315:657.</a></li><li><a class="nounderline abstract_t">Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 1972; 30:376.</a></li><li><a class="nounderline abstract_t">Fernandez CA, Stewart E, Panetta JC, et al. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol 2014; 73:1307.</a></li><li><a class="nounderline abstract_t">McCormick M, Lapinski J, Friehling E, Smith K. Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer 2021; 68:e29051.</a></li><li><a class="nounderline abstract_t">Verma A, Chen K, Bender C, et al. PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability. Pediatr Hematol Oncol 2019; 36:277.</a></li><li><a class="nounderline abstract_t">August KJ, Farooki S, Fulbright JM, et al. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer 2020; 67:e28021.</a></li><li><a class="nounderline abstract_t">Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972; 77:861.</a></li><li><a class="nounderline abstract_t">Carter JJ, McLaughlin ML, Bern MM. Bleomycin-induced fatal hyperpyrexia. Am J Med 1983; 74:523.</a></li><li><a class="nounderline abstract_t">Leung WH, Lau JY, Chan TK, Kumana CR. Fulminant hyperpyrexia induced by bleomycin. Postgrad Med J 1989; 65:417.</a></li><li><a class="nounderline abstract_t">Ma DD, Isbister JP. Cytotoxic-induced fulminant hyperpyrexia. Cancer 1980; 45:2249.</a></li><li><a class="nounderline abstract_t">Dinarello CA, Ward SB, Wolff SM. Pyrogenic properties of bleomycin (NSC-125066). Cancer Chemother Rep 1973; 57:393.</a></li><li><a class="nounderline abstract_t">Glovsky MM, Braunwald J, Opelz G, Alenty A. Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity. J Allergy Clin Immunol 1976; 57:134.</a></li><li><a class="nounderline abstract_t">Khansur T, Little D, Tavassoli M. Fulminant and fatal angioedema caused by bleomycin treatment. Arch Intern Med 1984; 144:2267.</a></li><li><a class="nounderline abstract_t">Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119:5661.</a></li><li><a class="nounderline abstract_t">Castleberry RP, Crist WM, Holbrook T, et al. The cytosine arabinoside (Ara-C) syndrome. Med Pediatr Oncol 1981; 9:257.</a></li><li><a class="nounderline abstract_t">Shah SS, Rybak ME, Griffin TW. The cytarabine syndrome in an adult. Cancer Treat Rep 1983; 67:405.</a></li><li><a class="nounderline abstract_t">Ek T, Pinkava M, Abrahamsson J. Ara-C fever and infections after high-dose ara-C treatment in pediatric lymphoid malignancies. J Pediatr Hematol Oncol 2005; 27:364.</a></li><li><a class="nounderline abstract_t">Ek T, Jarfelt M, Mellander L, Abrahamsson J. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol 2001; 37:459.</a></li><li><a class="nounderline abstract_t">Manoharan A. The cytarabine syndrome in adults. Aust N Z J Med 1985; 15:451.</a></li><li><a class="nounderline abstract_t">Williams SF, Larson RA. Hypersensitivity reaction to high-dose cytarabine. Br J Haematol 1989; 73:274.</a></li><li><a class="nounderline abstract_t">Rassiga AL, Schwartz HJ, Forman WB, Crum ED. Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization. Arch Intern Med 1980; 140:425.</a></li><li><a class="nounderline abstract_t">Markman M, Howell SB, King M, et al. Anaphylactic reaction to cytarabine: in vitro evidence that the response is immunoglobulin E mediated. Med Pediatr Oncol 1984; 12:201.</a></li><li><a class="nounderline abstract_t">Berkowitz FE, Wehde S, Ngwenya ET, et al. Anaphylactic shock due to cytarabine in a leukemic child. Am J Dis Child 1987; 141:1000.</a></li><li><a class="nounderline abstract_t">Hoetelmans RM, Schornagel JH, ten Bokkel Huinink WW, Beijnen JH. Hypersensitivity reactions to etoposide. Ann Pharmacother 1996; 30:367.</a></li><li><a class="nounderline abstract_t">Blanca M, Torres MJ, Girón M, et al. Successful administration of cytarabine after a previous anaphylactic reaction. Allergy 1997; 52:1009.</a></li><li><a class="nounderline abstract_t">Metz KA, Johnson T, Hershey GK, et al. Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome. Ann Allergy Asthma Immunol 2009; 102:173.</a></li><li><a class="nounderline abstract_t">Salles G, Vial T, Archimbaud E. Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration. Ann Hematol 1991; 62:74.</a></li><li><a class="nounderline abstract_t">Rosas-Vargas MA, Casas-Becerra B, Velázquez-Armenta Y, et al. Cyclophosphamide hypersensitivity in a leukemic child. Ther Drug Monit 2005; 27:263.</a></li><li><a class="nounderline abstract_t">Popescu NA, Sheehan MG, Kouides PA, et al. Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. J Allergy Clin Immunol 1996; 97:26.</a></li><li><a class="nounderline abstract_t">Khaw SL, Downie PA, Waters KD, et al. Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide. Pediatr Blood Cancer 2007; 49:341.</a></li><li><a class="nounderline abstract_t">Allergic reactions to mesna. Lancet 1991; 338:381.</a></li><li><a class="nounderline abstract_t">Case DC Jr, Anderson J, Ervin TJ, Gottlieb A. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552. Med Pediatr Oncol 1988; 16:182.</a></li><li><a class="nounderline abstract_t">Pratt CB, Sandlund JT, Meyer WH, Cain AM. Mesna-induced urticaria. Drug Intell Clin Pharm 1988; 22:913.</a></li><li><a class="nounderline abstract_t">O'Dwyer PJ, Weiss RB. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984; 68:959.</a></li><li><a class="nounderline abstract_t">O'Brien ME, Souberbielle BE. Allergic reactions to cytotoxic drugs--an update. Ann Oncol 1992; 3:605.</a></li><li><a class="nounderline abstract_t">Millward MJ, Newell DR, Mummaneni V, et al. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer 1995; 31A:2409.</a></li><li><a class="nounderline abstract_t">Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11:1080.</a></li><li><a class="nounderline abstract_t">Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86:12.</a></li><li><a class="nounderline abstract_t">Collier K, Schink C, Young AM, et al. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. J Oncol Pharm Pract 2008; 14:51.</a></li><li><a class="nounderline abstract_t">Damaske A, Ma N, Williams R. Leucovorin-induced hypersensitivity reaction. J Oncol Pharm Pract 2012; 18:136.</a></li><li><a class="nounderline abstract_t">Ureña-Tavera A, Zamora-Verduga M, Madrigal-Burgaleta R, et al. Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations. J Allergy Clin Immunol 2015; 135:1066.</a></li><li><a class="nounderline abstract_t">Alkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reactions to methotrexate. Cancer 1996; 77:2123.</a></li><li><a class="nounderline abstract_t">Kohli A, Ferencz TM, Calderon JG. Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma. Allergy Asthma Proc 2004; 25:249.</a></li><li><a class="nounderline abstract_t">MacGinnitie AJ, Walensky LD, Turvey SE, et al. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol 2003; 14:409.</a></li><li><a class="nounderline abstract_t">Davis KA, Williams P, Walker JC. Successful desensitization to high-dose methotrexate after systemic anaphylaxis. Ann Allergy Asthma Immunol 2003; 90:87.</a></li><li><a class="nounderline abstract_t">Lopes G, Vincek V, Raez LE. Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006; 51:247.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25:3958.</a></li><li><a class="nounderline abstract_t">Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.</a></li><li class="breakAll">Unpublished data from the phase III temsirolimus versus interferon in advanced renal cell cancer trial. Personal communication, Michael Atkins, MD, November 14, 2008.</li></ol></div><div id="topicVersionRevision">Topic 2835 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561172" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical features of hypersensitivity reactions to carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985812" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology of hypersensitivity drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985812" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of hypersensitivity drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461139" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753908" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Symposium on the definition and management of anaphylaxis: summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21262103" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780940" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and management of anaphylaxis in precision medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131563" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041891" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522249" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management and preparedness for infusion and hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18502492" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564516" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31918017" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allergy Evaluation of Hypersensitivity to Platinum Salts and Taxanes: A Six-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21462800" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A new rapid desensitization protocol for chemotherapy agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26895621" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3342471" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937414" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Carboplatin-induced immune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712487" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypersensitivity and idiosyncratic reactions to oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10513718" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oxaliplatin-induced haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757568" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serious delayed hypersensitivity reaction to oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16356307" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844841" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033714" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565767" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19149322" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of allergic reactions to oxaliplatin in colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21243395" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528251" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491759" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017531" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18754135" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/82473" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Germ cell tumors (II): VAB II in metastatic testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7025719" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520154" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478013" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715290" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Docetaxel administered on a weekly basis for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18098210" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797060" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19944454" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23867999" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255380" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282245" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypersensitivity reactions to oxaliplatin: experience in a single institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16865410" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246947" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12888815" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypersensitivity reactions related to oxaliplatin (OHP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648298" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypersensitivity Reactions to oxaliplatin: incidence and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648298" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypersensitivity Reactions to oxaliplatin: incidence and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19565364" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute renal failure related to oxaliplatin-induced intravascular hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979913" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19031966" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fatal thrombocytopenia after oxaliplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24188688" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826449" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28094039" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565621" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11855873" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175010" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Death from anaphylaxis to cisplatin: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039675" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnosis and management of hypersensitivity reactions caused by oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408510" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673050" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258305" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17703101" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19823066" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054201" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598359" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Skin testing and hypersensitivity reactions to oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501233" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432514" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22099941" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832325" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798707" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531847" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789084" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328672" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Carboplatin desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077926" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36701137" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Rechallenge After Oxaliplatin-Induced Hypersensitivity Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776524" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776524" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720178" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1384149" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725998" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2882837" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Phase I clinical and pharmacokinetic study of taxol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864222" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Systemic therapy emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636752" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11855881" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989941" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788579" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8103352" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Coping with toxicities of docetaxel (Taxotere).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12214584" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rituximab-induced serum sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720456" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12125509" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Taxol reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15205600" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1972736" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hypersensitivity reactions from taxol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486816" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391679" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7911160" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2452032" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Study of histamine release induced by acute administration of antitumor agents in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20461974" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568136" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Successful parenteral desensitization to paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663424" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779722" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294478" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862707" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Optimal use of docetaxel (Taxotere): maximizing its potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7857119" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974481" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427258" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721396" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hypersensitivity reactions to chemotherapeutic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16353140" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33762718" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The added value of H2 antagonists in premedication regimens during paclitaxel treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006754" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396407" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261533" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12442916" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34357780" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27911278" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779712" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12197222" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Premedication strategy for weekly paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519756" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29435713" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477638" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Practical aspects of weekly docetaxel administration schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918162" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809523" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18420499" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Weekly paclitaxel in the adjuvant treatment of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12184412" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Implementation and results of a test dose program with taxanes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098057" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Successful re-treatment with taxol after major hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902427" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Paclitaxel rechallenge failure after a major hypersensitivity reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721432" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006516" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135470" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172456" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34963337" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820391" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147780" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436520" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888992" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3349287" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Allergic reaction to intravesical adriamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3735544" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6237897" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Doxorubicin-induced hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/160837" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : "Adriamycin flare": a skin reaction resembling extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361959" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Safety aspects of pegylated liposomal doxorubicin in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954584" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2348224" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10500842" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17132721" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25348002" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457414" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31099289" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735901" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6932563" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Delayed allergic reactions following intramuscular L-asparaginase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24498943" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862348" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29115886" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Severe pegaspargase hypersensitivity reaction rates (grade≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/295576" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377776" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Hypersensitivity reactions to oxaliplatin and other antineoplastic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7037164" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/337095" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593262" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22042277" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26549586" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26549586" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26549586" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26461960" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Allergic reactions associated with pegaspargase in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9614257" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613779" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7850718" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24516026" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228505" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228505" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31188727" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516438" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484422" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9766495" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26928249" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449211" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358966" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31099154" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31099154" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31099154" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2943992" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4559405" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771103" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33860989" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296092" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571395" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4118759" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6187214" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Bleomycin-induced fatal hyperpyrexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2481850" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Fulminant hyperpyrexia induced by bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6155201" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Cytotoxic-induced fulminant hyperpyrexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4128421" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Pyrogenic properties of bleomycin (NSC-125066).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1249347" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6208860" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Fulminant and fatal angioedema caused by bleomycin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22555973" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6941069" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : The cytosine arabinoside (Ara-C) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6601987" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : The cytarabine syndrome in an adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012325" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Ara-C fever and infections after high-dose ara-C treatment in pediatric lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745875" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3866543" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : The cytarabine syndrome in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2530999" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Hypersensitivity reaction to high-dose cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6928748" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727776" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Anaphylactic reaction to cytarabine: in vitro evidence that the response is immunoglobulin E mediated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3475975" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Anaphylactic shock due to cytarabine in a leukemic child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8729891" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Hypersensitivity reactions to etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360753" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Successful administration of cytarabine after a previous anaphylactic reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230475" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031970" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15905792" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Cyclophosphamide hypersensitivity in a leukemic child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568134" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333822" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677714" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Allergic reactions to mesna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132591" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3148455" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Mesna-induced urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6744346" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Hypersensitivity reactions induced by etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1450041" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Allergic reactions to cytotoxic drugs--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652278" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501494" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857004" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337441" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248170" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Leucovorin-induced hypersensitivity reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25457996" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640680" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Anaphylactoid reactions to methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15510585" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14641613" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12546343" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Successful desensitization to high-dose methotrexate after systemic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360237" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Pemetrexed-associated urticarial vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761980" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538086" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
